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Abstract 
Low birth weight (LBW), and maternal Western Diet (WD) consumption have both been 
independently implicated to increase the risk of developing cardiovascular diseases (CVDs) in 
later life. These fetal programmed risks are also believed to exacerbate the effects of a postnatal 
WD pattern, therefore resulting in the development of pre-clinical markers of CVDs, such as 
insulin resistance (IR), coronary circulation disruptions. This thesis aimed to elucidate the roles 
of sub-optimal in utero growth through placental insufficiency, or chronic maternal WD 
consumption, and postnatal WD consumption on the long-term programming of CVDs in a 
guinea pig model. Early pre-clinical markers of CVD development including reduced coronary 
flow, left ventricular hypertrophy, and fibrosis were observed in the young LBW offspring. 
Postnatal consumption of WD was itself strongly associated with the early development of 
cardiac IR. Collectively these findings suggests that prenatal insults combined with a postnatal 
dietary insult, can lead to an increased risk of developing CVDs. 
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Chapter 1  
 
1 Literature Review 
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1.1 Cardiovascular Diseases 
 
The burdens of chronic non-communicable diseases (NCDs) are becoming more 
apparent in today’s society. According to the World Health Organization, NCDs are 
responsible for approximately nine million of all premature deaths before the age of 60. In 
particular, low and middle income countries are especially susceptible to NCDs, where 
they make up 90% of all NCD related premature deaths. Of the many types of NCDs, 
cardiovascular disease (CVD) distinguishes itself ahead of cancers, respiratory diseases 
and diabetes as the leading cause of NCD related deaths. In 2008 alone, approximately 17.3 
million people worldwide died from CVDs, with a mortality rate of 17%1,2. Unfortunately, 
this figure is expected to rise in the future, with an estimated growth to 24% of all 
mortalities1,2.  
These alarming trends can be attributed to the increasing prevalence of risk factors 
for CVDs in both developing and developed countries. These risk factors include tobacco 
use, physical inactivity, obesity, and dietary choices such as the consumption of foods high 
in sugars and/or saturated fatty acids3–5. In addition, prenatal complications and the 
associated low birth weight (LBW) are also recognized by the United Nations as factors 
which predispose an individual to the development of heart diseases and obesity in 
adulthood6. Collectively these risk factors contribute to the development of different types 
of CVDs, including coronary artery disease, congenital heart diseases, hypertension, and 
cardiomyopathy. In particular, cardiomyopathy, with its asymptomatic nature, and ties to 
both prenatal and postnatal risk factors, presents a substantial risk to our society, and is 
therefore an important area of focus7,8. 
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1.1.1 Cardiomyopathy 
 
Cardiomyopathy is defined as the disease of the myocardium associated with 
mechanical or electrical dysfunction, leading to cardiovascular death and progressive heart 
failure8,9. In a 2010 study by the American Heart Association, cardiomyopathy affects 
approximately 2.6% of the US population with a mortality rate of 56.3%, costing the health 
care system approximately $39.2 billion10. Patients with cardiomyopathy experience 
shortness of breath, fatigue, and chest pain; however, many remain asymptomatic7,8.  
Cardiomyopathy can be categorized into two major groups: primary or secondary. 
Primary cardiomyopathies are solely confined to the heart, while secondary 
cardiomyopathies result from conditions which affect other parts of the body such as 
Gaucher disease and diabetes11. A common type of primary cardiomyopathy is 
hypertrophic cardiomyopathy, where the enlargement of cardiomyocytes results in the 
asymmetric thickening of the left ventricle, increase in left ventricular stiffness, and 
ischemia9,12. The etiology of hypertrophic cardiomyopathy is familial or genetic, but can 
also develop over time from chronic high blood pressure9,12. Clinically, hypertrophic 
cardiomyopathy is characterized by a hypertrophied myocardium and an un-dilated left 
ventricular chamber. In comparison, another type of the disease is dilated cardiomyopathy, 
where the enlargement of cardiomyocytes results in the stretching and thinning of the left 
ventricle and a dilated ventricular chamber13.  Dilated cardiomyopathy is non-ischemic in 
nature, and although categorized as a primary type of the disease, it is idiopathic, with 
probable causes such as infections, genetic factors, diabetes, and heart attack7,9. While both 
hypertrophic and dilated cardiomyopathy have different causes and pathophysiology, they 
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do, however, share a common feature, which is cardiomyocyte enlargement. This process, 
otherwise known as cardiac hypertrophy, is an important risk factor in myocardial 
infarction, sudden death, and nearly all forms of heart failure including cardiomyopathy14. 
 
1.1.2 Cardiac Hypertrophy  
 
The heart is composed of cardiomyocytes (muscle cells) and non-myocytes such as 
fibroblasts and endothelial cells15. As a post-mitotic organ, cardiomyocyte proliferation 
normally occurs in utero.  Shortly after birth, cardiomyocytes lose the ability to proliferate, 
and as a result, postnatal cardiac growth is dependent on cardiomyocyte enlargement and 
the proliferation of non-myocytes16,17. Often, in response to chronic increases in functional 
load, ventricular wall stress, and load which the blood is ejected against, intrinsic mechano-
sensing mechanisms which signals the enlargement of heart mass are activated. This 
cardiomyocyte enlargement is defined as cardiac hypertrophy, and is a major component 
of cardiac remodelling18–20.  
Hypertrophic growth can be classified as concentric or eccentric depending on the 
change in cardiomyocyte shape. In concentric hypertrophy, the increase in cardiac myocyte 
width in response to pressure overload results in the thickening of the ventricular wall and 
minor reductions in chamber volume. In comparison, eccentric growth is the increase in 
cardiomyocyte length in response to volume overload, which results in increased chamber 
volume with decreased or unaltered wall thickness21,22. Cardiac hypertrophy can be further 
classified as either physiological or pathological hypertrophy. Physiological hypertrophy 
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is exercise induced, with normal cardiac morphology, and is typically reversible23. In 
contrast, pathological growth occurs as a result of increased load in a disease setting such 
as myocardial infarction, coronary artery disease, and cardiomyopathy14. Depending on the 
nature of the disease, such as pressure or volume overload, pathological hypertrophy can 
occur under concentric or eccentric growth promoting conditions. In addition to increased 
heart and cardiomyocyte size, pathological hypertrophy is also accompanied by 
cardiomyocyte death, and fibrosis14,24,25. More worryingly, over 50% of all hypertrophy-
related deaths in adults are sudden, with minimal or no prior symptoms26. Given the high 
prevalence of hypertrophy related cardiac dysfunctions, and the sudden nature of 
hypertrophy-related deaths27,28, it is important to examine possible markers of CVD 
development for diagnostic and intervention purposes. 
 
1.1.3 Preclinical Metabolic Markers of CVD Development 
 
The main source of energy generation in the heart is from fatty acid oxidation 
(~70% of ATP production), while glucose metabolism accounts for approximately 30% of 
ATP production. In order to maintain a steady supply of energy, the heart is also capable 
of switching between energy sources in order to adapt to different workloads, or fuel 
molecules29. Interestingly, in the early stages of pathological hypertrophy, a decrease in 
fatty oxidation and increase in glucose metabolism is observed30–32. This switch towards 
glucose metabolism often occurs during the early stages of CVDs, and mirrors the 
metabolic patterns of a fetal or newborn heart33. However, like the fetal heart, glucose 
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transport is mainly handled by the insulin independent glucose transporter 1 (GLUT1) 
rather than the insulin dependent GLUT4. This results in a reduction in GLUT4/GLUT1 
ratio, and insulin dependent glucose uptake34,35. While this mechanism is initially 
protective against further disease progression (e.g. increasing blood pressure, and reducing 
coronary blood flow). However, ATP production falls as glucose uptake and metabolism 
is progressively reduced with the emergence of insulin resistance (IR), a key pre-clinical 
marker associated with developing CVD36–38.  
A canine model of advanced dilated cardiomyopathy demonstrated that myocardial 
IR and increases in fatty acid concentration occurred in parallel with CVD disease 
progression39. Additionally, in severe cases of cardiomyopathy, ATP levels are decreased 
along with the impairment of cardiac insulin signaling pathways39. It can be inferred that 
IR is associated with decreased ATP stores during a period of crucial dependence on 
glucose uptake and utilization39. Other studies have also suggested that the development of 
cardiac IR is in fact a protective mechanism against heart failure, particularly in the 
presence of a high-saturated fat diet40. For example, insulin resistant rats with mild to 
moderate heart failure that were fed a high fat diet exhibited decreased glucose utilization, 
but preserved contractile function40. The reduction in glucose metabolism was likely 
compensated by increased fatty oxidation41, and that the insulin resistant animals were 
therefore forced to use fatty acid oxidation as a means for energy production. This in turn 
would direct fatty acids to productive pathways such as β-oxidation and triglyceride 
synthesis, which therefore reduce the formation of lipotoxic intermediates such as 
diacylglycerol (DAG) and ceramides to preserve cardiac function40,42. Nonetheless, the 
implications of cardiac IR are still poorly defined. However, it is apparent that its 
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development, along with alterations in glucose uptake is often in concert with CVDs such 
as cardiomyopathy.  
Under normal circumstances, cardiac glucose uptake is mediated by insulin 
dependent glucose transporters GLUT4 and insulin independent GLUT1, which accounts 
for approximately 60% and 40% of all glucose uptake in the heart respectively43. Both 
transporters are widely distributed in fetal tissues. However, while GLUT1 is membrane 
bound and insulin independent, GLUT4 activity requires its translocation to the membrane, 
a process mediated by the insulin signaling pathway44. Interestingly, although GLUT1 
activity is classically non-insulin dependent, recent evidence shows that insulin may play 
a minor role in GLUT1 translocation during diabetic stages45. In inducing GLUT4 
transporter proteins to the cell membrane, insulin first binds to insulin receptor on the cell 
surface, which leads to the phosphorylation of insulin receptor, tyrosine phosphorylation 
of insulin receptor substrate (IRS), the activation PI3-kinase, and phosphorylation of AKT 
(protein kinase B) at Threonine 308 and Serine 473. Activated AKT and PI 3-kinase is then 
involved in promoting the translocation of GLUT4 from intracellular storage to the plasma 
membrane46. This signaling pathway, particularly Phosphoinositide 3- Kinase (PI3-K) 
activation, is necessary for insulin stimulated glucose uptake. However, during states of IR 
when the action of insulin is impaired, there appears to be a decrease in insulin associated 
stimulation of IRS and PI3-kinase, and activation of AKT. This ultimately results in a 
decrease of GLUT4 translocation, and a reduction in glucose uptake and metabolism47. 
Taken together, given that this state of myocardial IR typically precedes the onset of severe 
CVDs, early detection of changes in myocardial insulin sensitivity and glucose uptake may 
be an effective early predictor CVD48. 
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1.1.4 Coronary Blood Flow as Markers of Cardiomyopathy Development 
 
With the increasing severity of myocardial IR and CVD development, comes 
progressive injury to the coronary circulation37. For example, in the previously mentioned 
canine model of advanced dilated cardiomyopathy, progressive hemodynamic impairment 
in coronary blood flow also occurred in parallel with myocardial IR and increasing severity 
of cardiovascular complications39. Symptoms of coronary vascular dysfunction are often 
found in patients with cardiomyopathy. A substantial body of evidence also suggests that 
reductions in coronary blood flow is a key marker in the development of 
cardiomyopathy49,50. For instance, coronary blood flow, as determined by Positron 
Emission Tomography (PET), was particularly blunted in patients later identified with 
severe heart failure or death51. Similarly, patients with dilated cardiomyopathy also 
displayed reduced coronary blood flow in conjunction with cardiac enlargement52. It is 
clear from these studies that impairments in coronary flow underlie the development of 
many CVDs. Furthermore, an Italian study of patients with various degrees of left 
ventricular dysfunction suggests that coronary blood flow reduction  is a stronger predictor 
of risk of death and development of heart failure than other common clinical prognoses 
such as echocardiography53. The effects of IR on coronary circulation remains to be 
elucidated. However it is clear that progressively worsening coronary circulation function 
occurs with increasing severity of IR. A possible underlying factor may be the abnormal 
insulin mediated,  nitric oxide dependent vasodilation during IR54. Nevertheless, it is 
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evident that coronary blood flow is a reliable predictor of systolic dysfunction and 
developing heart failure associated with cardiac remodeling processes. 
 
1.1.5 Cardiac Remodeling Consequences 
 
Pathological hypertrophy is characterized in the later disease stages by 
cardiomyocyte enlargement, and the onset of fibrosis, resulting in the thickening and 
stiffening of the ventricular wall52. These cardiac remodeling processes are considered a 
crucial component leading to systolic dysfunction, and impediment of contractility. 
Furthermore, there are compelling evidence which suggests that the reduction in resting 
coronary flow may be associated with the expansion of extra-cellular space and ventricular 
dilation52. Specifically, the onset of fibrosis from an excessive expression of collagen is 
associated with diminished capillary density and myocardial ischemia55. Myocardial 
capillaries are known to be the primary determinant of coronary microvascular flow. 
Reductions in capillary density may result in higher capillary resistance, which requires 
arteriole and vein vasodilatation to maintain blood flow56. This has been observed in 
patients with dilated cardiomyopathy where, despite the appearance of normal coronary 
arteries, reduction in myocardial capillary density was strongly associated with reduced 
coronary blood flow and heart failure57. In addition, the accumulation of collagen in the 
cardiac interstitium (interstitial fibrosis) in cases of heart failure may also lead to a decrease 
in capillary density, subjecting cardiac myocytes to a state of hypoxia58.  
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The development of CVDs such as cardiomyopathy are characterized by cardiac 
remodeling processes such as hypertrophy and fibrosis, as well as alterations in cardiac 
glucose metabolism and insulin sensitivity. As these factors accumulate, they lead to the 
development of systolic dysfunction, heart failure, and ultimately, death. Given the clear 
metabolic and functional consequences of CVDs such as cardiomyopathy, early detection 
of these markers prior to the onset of severe disease phenotypes is crucial for interventional 
therapies. Traditionally, risk factors for the development of CVDs are primarily postnatal. 
However, emerging evidence suggests that the origin of these chronic adult diseases may 
be as early as during the in utero period59. Therefore, a key question in this thesis is whether 
prenatal insults, combined with the traditional postnatal factors for CVDs, can lead to the 
early development of CVDs. 
 
  
11 
 
1.2 Developmental Origins of Health and Disease 
 
1.2.1 Intrauterine Growth Restriction and Low Birth Weight 
 
According to the World Health Organization, the worldwide prevalence of low 
birth weight babies (LBW; <2500g) is at approximately 15.5%60. Specifically, the Canada-
wide occurrence of LBW is lower at 5.9%. LBW infants are often a consequence of sub-
optimal in utero environments, such as in cases of intrauterine growth restriction (IUGR). 
Clinically, growth restriction can be defined as birth weight falling below the 10th 
percentile for a specific sex of gestational age60. This inability of the fetus to reach its 
expected growth potential may impart significant risks in perinatal morbidity and 
mortality61,62. Interestingly, studies have demonstrated that offspring beyond the arbitrary 
birthweight cut-off in the clinical IUGR categorization can also be exposed to an adverse 
in utero environment, and display the same complications in adulthood63. This is 
exemplified by reports of offspring above the clinical birthweight cut-off displaying 
markers of poor in utero growth, such as thinness at birth, and pattern of rapid postnatal 
catch-up growth64. Therefore, a potentially larger number of adversely grown offspring 
may be at risk for later life complications such CVDs than what the traditional measures 
suggest. Given the increasing risk of developing metabolic diseases in later life, and the 
potentially higher cost of treating later life disease as opposed to early invention programs, 
it is imperative that we understand the etiology, and underlying mechanisms of growth 
restriction and fetal programming59,65.   
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A reliable diagnosis of IUGR infants is crucial to understanding the effects of 
growth restriction on the development of complications in later life. Traditionally, the use 
of Ponderal index, the ratio of weight/(height3), is an excellent assessment of neonatal 
growth retardation, and is positively correlated with fetal nutritional status at term66,67. 
Furthermore, IUGR can be classified under two distinct patterns of growth abnormality: 
symmetrical, or asymmetrical, therefore, careful attention to body and growth relationships 
are essential in understanding the in utero growth regime68.  Symmetrical IUGR, which is 
the proportionate decrease of fetal abdomen and head growth, results in a normal Ponderal 
index. It is generally associated with early fetal insults during the first or second 
trimester69,70. Asymmetrical IUGR in comparison, refers to the disproportionate decrease 
in fetal abdomen and head growth, known as the “brain sparing” effect, and is the most 
common form of IUGR (~70%). This is attributed to the ability of the fetus to adapt, and 
redistribute its cardiac output to essential circulations such as cerebral, and coronary 
circulation in response to insults during the last trimester71,72.  
 The causes of IUGR are multifactorial and can be summarized into three major 
scenarios: inadequate maternal supply of oxygen and nutrients, inability of fetus to fully 
utilize the supply of oxygen and nutrients, and abnormal placental function 71. Maternal 
complications such as hypertension, diabetes, and under-nutrition accounts for 
approximately 25-30% of IUGR cases73. For example, maternal hypoxia in conditions such 
as pulmonary diseases and hypertension are often associated with growth restricted 
fetuses74,75. To a lesser extent, fetal disorders, including genetic diseases, and congenital 
malformations are also associated with the development of IUGR76. According to the 
Metropolitan Atlanta Congenital Defects Program, approximately 38% of chromosomally 
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abnormal infants displayed signs of IUGR77. Lastly, because fetal growth and development 
is largely dependent on oxygen delivery. It can therefore be inferred that normal placental 
development is integral for the transport of oxygen and nutrient to the fetus, and 
maintaining a healthy pregnancy. Furthermore, smaller placentas, and reduced placenta to 
fetal weight ratio are associated with growth restricted infants78. A common complication 
which plagues the prevalence of growth retardation is placental insufficiency.  
 
1.2.2 Placental Insufficiency 
 
Placental insufficiency (PI) is the inability of the placenta to provide the required 
transport of oxygen and nutrients to fully support the developing fetus. PI is known to be 
responsible for the majority of IUGR cases, and a critical component is fetal hypoxia79,80. 
Although the mechanisms underlining the development of PI are idiopathic, these 
idiopathic pregnancies and fetal hypoxia occur due to natural placental development 
failures81,82.  Normally, as gestation advances, the growing vascular network and decrease 
in vascular resistance, results in the increase in both uterine and umbilical blood flow83,84. 
However, as PI develops, vascular growth is impaired, and vascular resistance in umbilical 
and uterine arteries increases, resulting in a 2.5 fold reduction in absolute blood flow85–87.  
Studies have also postulated that abnormal fetal trophoblast invasion of maternal decidua 
is associated with an impaired transformation of spiral arteries into low resistance vessels, 
thus reducing utero-placental blood flow88. It is thus evident that when the placenta fails to 
supply the fetus with adequate oxygen and nutrients, fetal growth will fall from its genetic 
trajectory and result in growth restriction89 
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1.2.3 Fetal Programming and Catchup Growth 
 
The theory of fetal programming suggests that insults during gestation may impair 
the growth of the fetus, and can lead to the development of chronic diseases in later life59. 
The association between growth in utero and adult disease development was first 
developed by Forsdahl in the 1970s. Using official statistical data in Norway, Forsdahl 
reported that poor environments in childhood and adolescence followed by periods of 
prosperity was correlated with the risk of coronary heart disease90. Moving forward to the 
1980s, Barker and colleagues also reported a strong correlation between LBW and later 
life development of coronary heart diseases in England and Wales91. In addition, using the 
official Hertfordshire medical records from 1911-1930, Barker also reported that LBW was 
associated with the development of IR at a mature age of 6492. These studies eventually 
spawned the Forsdahl-Barker hypothesis, then later, the Developmental Origins of Health 
and Disease hypothesis, which recognized that development of chronic metabolic diseases 
in later life are a result of programming mechanisms during critical periods of in utero life.  
Further support for the idea that the prenatal period represents a critical period in 
later life disease development is highlighted by the study of the Dutch hunger winter at the 
height of the Second World War. As a result of the German occupation and blockade, 
civilians in the Netherlands experienced a famine during the winter of 1944. Individuals 
born during this period with maternal caloric restrictions displayed a 300 gram decrease in 
average birth weight, and in later life, an impaired glucose tolerance compared to those 
born prior to the incident93,94.  
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 In response to inadequate in utero environments, the fetus may be programmed for 
a nutritionally poor postnatal environment95,96. However in setting this phenotype, a 
mismatch of postnatal environment can also predispose the individual to later life 
development of chronic diseases. This can be highlighted by examining the events of the 
Leningrad siege during the Second World War. These studies demonstrated that the 
glucose tolerance of individuals born during the siege (exposed to the famine) were not 
different from the individuals born after the siege97. This observation may seem at odds 
with previous example of the Dutch hunger winter, however this discrepancy can be 
explained by a major difference between the two events. While the Dutch hunger winter 
lasted for 6 months, the Leningrad siege lasted for 28 months. Victims from the Leningrad 
siege were therefore born into the famine and experienced a low nutrient diet longer than 
those of the Dutch hunger winter98. Thus, it can be inferred that unlike their counterparts 
in Leningrad, infants of the Dutch hunger experienced a mismatched postnatal environment 
of high nutrient intake, which resulted in the programmed IR in adulthood. These studies 
also highlights the postnatal period as another critical period in the development of diseases 
in later life. Therefore warranting our attention to the concept of “catch-up growth”.  
A postnatal “catch-up growth” describes the accelerated postnatal growth profile 
which compensates for restricted growth during prenatal life, and is usually associated with 
asymmetrical growth restricton69. However many studies have associated this accelerated 
growth trajectory with the development of diseases in adulthood. For example, similar to 
the original Barker studies, a longitudinal study in Finland demonstrated that women born 
of LBW and experienced rapid postnatal growth were associated with the development of 
coronary heart disease in later life99.  In another study, this “catch-up growth” in LBW 
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children was also strongly associated with an impaired glucose tolerance at seven years of 
age100. Alarmingly, this accelerated period of growth resulting from sub-optimal in utero 
environments, is highly correlated with CVD development. A Finnish study reported that 
the highest death rates from coronary heart disease were from children who were thin at 
birth, but had caught up to average body weight by childhood101. These studies provide 
strong evidence for the role of “catch-up growth” in exacerbating growth restricted 
individuals and programming of diseases in later life. Interestingly, the current arbitrary 
birth weight cut-off in IUGR categorization cannot account for the possibility that 
newborns above the 10th percentile can also be exposed to an adverse in utero 
environment63. The inappropriate growth patterns associated with insufficient in utero 
environments can still be present despite not being reflected in birth weight outcomes. In 
support, a study reported that accelerated growth during the first 4 months of post-natal life 
is associated with childhood obesity, and is also independent of birth weight64. Therefore 
inferring that the accelerated growth pattern maybe a more crucial factor behind the adverse 
health outcomes than birth weight alone. In support, risk of chronic disease development 
have also been demonstrated to occur independent of birth weight102,103. This highlights the 
possibility that the risk of disease development is not solely caused by a drop in 
birthweight, but by a combination of in utero induced stress factors, and an accelerated 
growth pattern. As a result, it is important to further examine the underlying processes 
behind fetal programming of CVD development in later life and the contributions of a 
postnatal catch up growth. 
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1.2.4 Fetal Programming of CVDs 
 
Barker and colleagues initially demonstrated that mortality from heart diseases are 
strongly associated with fetal programming, both animal and human studies continued to 
support Barker’s original work and add further understanding to the in utero programmed 
mechanisms underlying development of diseases in later life104–106.  
Mechanisms such as in utero hypoxia have been known to alter heart development, 
and suppress cardiac contractility107,108. Specifically, in utero insults are also associated 
with the development of cardiac hypertrophy, and cardiac remodeling. For example, the 
expression of pro-fibrotic genes, with discrete structural abnormalities such as deposition 
of collagen in the heart at adolescence have been found in rats born of hypoxic IUGR109. 
Additionally, rats born from a hypoxic pregnancy also displayed left ventricular 
enlargement at 12 months of age with strong indication of left ventricular dysfunction and 
pulmonary hypertension110. Collectively, these studies suggests that IUGR individuals may 
be predisposed to the development of CVDs in later life through these progressive cardiac 
remodeling situations.  
The programming of CVD such as cardiomyopathy may stem from placental 
insufficiencies given that the placenta regulates flow of oxygen and necessary nutrients for 
the fetus’ development. Amounting evidence have linked later life cardiovascular problems 
early markers such as disturbed endothelial function, and persistent alterations in cardiac 
metabolisms111,112. These manifestations can be traced back to the in utero environment. 
For example, impedance to placental blood flow, a characteristic of PI, often results in the 
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increase in placental bed resistance113,114. In order to overcome the mechanical force 
required to eject against a high resistance vascular bed, abnormal fetal heart growth 
typically occurs as adaptation. During post-natal life, this is associated with an increased 
ventricular load, which can contribute to the development of cardiac hypertrophy113,114. 
Interestingly, heart weights are not always altered in the placental restricted offspring, 
however there is certainly a higher proportion of mononucleated cardiomyocytes as 
demonstrated in a sheep model115. Furthermore, cardiomyocyte size relative to heart size 
is increased in the placental insufficient offspring. Normally, cardiomyocytes undergo 
binucleation during late gestation. However due to environmental factors such as placental 
restriction, this process – an indicator of heart maturation –  is delayed116,117. As a result, 
chronic placental restriction results in delayed binucleation during development, and larger 
but fewer cardiomyocytes at term115. These adaptions to chronic placental restriction are 
risk factors for the development of cardiac hypertrophy in adulthood, and can have long 
term consequences in later life. These studies altogether indicate the importance of fetal 
programming as a predictor of cardiovascular complications in later life. In summary, it is 
clear that in utero environments play a crucial role in later life disease development through 
inappropriate growth adaptations. Furthermore, these adaptations, when challenged by 
additional insults such as an unhealthy dietary pattern, can further increase the 
susceptibility to CVD development in the offspring. 
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1.3 Adverse Postnatal Diets 
 
As previously mentioned in the fetal programming discussion, another critical 
period in determining development of chronic diseases is the postnatal period. Specifically, 
a mismatch between prenatal and postnatal environment can lead to the development of 
metabolic complications in later life, as demonstrated by the Dutch hunger winter93. An 
increasing concern in our modern society is believed to affect this said critical postnatal 
growth period. This concern is  known as the “Western Diet” (WD), which is characterized 
by high saturated fats, and high sugar contents118,119. According to the World Health 
Organization, the consumption of this energy-dense diet combined with the lack of physical 
activity are the fundamental causes of obesity. Recent estimates of world-wide obesity rates 
is at 10%, with more than 40 million children categorized as overweight or obese120. As 
American corporations expand their fast food empire into developing countries, rates of 
obesity has also risen approximately 30%120. It therefore draws to our attention, how the 
mismatch between restricted in utero environments and an energy dense postnatal diet may 
affect health in adulthood  
 
1.3.1 Cardiovascular Dysfunction and WD 
 
The most concerning aspect of the consumption of a WD and increased Body Mass 
Index (BMI) is the risk of developing CVDs in adulthood120. In an eight year study, men 
aged 40-75 years whom, according to a questionnaire, declared a frequent consumption of 
WD had a higher risk of developing cardiovascular diseases compared to men who 
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primarily consumed a prudent diet121. A more recent study using logistic regression 
demonstrated that, after adjusting for coronary risk factors, women whom consumes 
processed meats, and sugars have a higher relative risk for heart diseases119. These 
epidemiological studies demonstrates that unhealthy dietary patterns such as the WD 
closely predicts the risk of CVDs later in life. Several animal studies also attempted to 
investigate the underlying mechanisms of this association. For example, a recent study 
demonstrated that rats fed with a high fat diet were associated with mild reduction in 
ejection fraction, increased left ventricular mass and IR122.  As previously discussed, a state 
of IR in the heart is strongly associated with cardiac remodeling and heart failure123. 
However, this insulin resistant state can be attributed to the consumption of diet high in 
fats such as the WD. In response, to the high levels of fatty acids, cardiomyocytes increase 
its expression of CD36 transporter for fatty acid uptake, and reduce GLUT4 mediated 
glucose uptake124,125.  Maladaptation in the saturated fatty acid oxidation often leads to the 
increase in its by-product: reactive oxygen species (ROS), and the accumulation of lipid 
intermediates such as diacylglycerol (DAG), and ceramide126. In turn, ROS and DAG are 
associated with the inhibition of serine phosphorylation of IRS-1 in the insulin signaling 
pathway. In addition, ceramide is also associated with the inhibition of AKT127. As a result, 
increased saturated fatty acids, and lipid intermediates can impair the heart’s ability to 
uptake glucose, resulting in IR. Furthermore, ROS is also associated with cardiac 
hypertrophy, where it has been shown to activate mitogen-activated protein kinases, and 
matrix metalloproteinase (MMP) involved in extracellular matrix remodeling and 
fibrosis128,129.  
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 Despite its importance to cardiac metabolism, the consequences of the change 
towards fatty acid oxidation is not completely understood. Take for example a study in 
2006 which examined the effects of high fat diets on the development of left ventricular 
remodeling in response to hypertension. Compared to a low fat diet, rats fed on a high fat 
diet (60% of total energy) did not demonstrate increases in left ventricular mass, myocyte 
cross-sectional area130. This suggests that a switch towards increased fatty acid oxidation 
can improve heart failure outcomes of hypertensive, and high fat diet fed rats. However, 
other studies have suggested that this may be due to the differential effects of saturated and 
unsaturated fatty acid content. Specifically, rats fed on saturated fatty acids demonstrated 
increased cardiomyocyte apoptosis compared to rats fed on unsaturated fatty acids, 
possibly due to an association with increased ceramide content131. In addition, another 
study demonstrated that rats developed contractile dysfunction when fed a WD (which 
contains a higher carbohydrate content), but not when fed a strictly high-fat diet118. This 
difference may be attributed to the fatty acid oxidation maladaptation, and the induction of 
fatty acid responsive genes associated with WD feeding. Considering the evidences 
presented, fatty acid oxidation surely plays an important and dynamic role in the 
development of heart failure. It is also evident that prolonged WD feeding is indeed 
associated with development of heart failure and cardiac remodeling due to maladapted 
fatty acid oxidation. With a significant portion of our population already predisposed to 
later life CVD development from in utero origins, the consumption of such unhealthy 
dietary patterns may exacerbate the existing consequences. Particularly, it can result in an 
earlier expression of the disease phenotype, and thus warrants our attention to new reliable 
diagnosis techniques in order to provide earlier intervention.  
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Marker of sub-optimal in utero growth 
Abnormal Placental Function 
(Placental Insufficiency, 
Hypoxia) 
Maternal Complications 
(Diabetes, Obesity) 
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Figure 1.1 Prenatal and Postnatal Factors That May Contribute to the Development 
of Cardiovascular Diseases in Adult Life. In utero insults such as PI, or poor maternal 
diet induces an unfavorable intrauterine environment, resulting in intrauterine growth 
restriction, and a low birth weight outcome. This predisposes the offspring to a period of 
rapid catch-up growth, associated with development of many adult diseases. This can be 
further aggravated by a postnatal insult from WD consumption. By adulthood, this may 
lead to the emergence of markers of CVDs such as IR, and disruptions in coronary blood 
flow. Eventually, these factors contribute to the development of a severe CVD. 
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1.4 Methods for Studying Cardiac Blood Flow and Metabolism 
 
1.4.1 Doppler Ultrasound 
 
Although currently there are no clinical technique available which allows the direct 
visualization of the coronary microcirculation, techniques which measures coronary blood 
flow are commonly used to assess the function of microvasculature. Several of these 
techniques utilizes the Doppler principle which allows the measurement of instantaneous 
changes in coronary blood flow. One such example is the Doppler catheter technique. 
Introduced in the 1970s by Hartley and Cole, it utilizes a piezoelectric crystal tipped 
catheter placed at the coronary ostium132,133. In addition, the introduction of the Doppler-
tipped guide wires, the 90s also saw the use of intracoronary flow measurement as an 
accepted approach in coronary blood flow measurements134. This method utilizes a thin 
flexible steerable guide wire with an ultrasound transducer tip which is placed in the left 
circumflex coronary artery. It offers improvement over the thicker Doppler catheters which 
are prone to alteration of velocity profile and obstruction of vessel135. Both of the Doppler 
techniques have already been established as useful techniques, however they require 
invasive catheterization, which may limit its usefulness as a clinical assessment of CVD 
development. In addition, although the use of Doppler catheters or wire are determined to 
be safe, severe complications such as bradycardia and coronary spasms can occur134. As a 
result, a safer, and equally reliable non-invasive technique in coronary flow, and perfusion 
measurements should be explored. 
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1.4.2 Echocardiography 
 
Echocardiography is performed by placing an ultrasound transducer on the chest 
wall of the subject, which creates two-dimensional images of the heart136. It can provide 
detailed information such as ventricular wall thickness, and the size and shape of the heart. 
In addition, it is also capable of calculating ejection fraction, cardiac output and diastolic 
function by estimating the changes of ventricle size during diastole and systole137. As a 
result, the use of echocardiography is common amongst physicians for the diagnosis of 
cardiomyopathies and hypertrophy. Additionally advancements in ultrasound technology 
also allows the measurement of coronary flow using the Transthoracic Doppler 
Echocardiography (TTDE) technique. Specifically, the TTDE utilizes pulsed wave 
Doppler echocardiography and color Doppler flow mapping for the measurement of  flow 
at the left anterior descending coronary artery136,138. The advantageous of 
echocardiography is that it provides a non-invasive assessment of various heart functions 
with no known risks or side effects. However results from echocardiography may be very 
operator dependent, and thus lack specificity139. More importantly, the measurement of 
heart functions such as cardiac output are end point measurements, and not early diagnostic 
targets prior to the onset of diseases. 
 
1.4.3 Positron Emission Tomography 
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Positron Emission Tomography (PET) is a highly sensitive modality which 
provides localization of radioactively labeled tracer concentrations through the detection 
of gamma rays resulting from positron annihilation140. These tracers can provide important 
hemodynamic and metabolic information. In patients with hypertrophic cardiomyopathy, 
coronary blood flow reserve measured with 15O-labelled water and 13N-labelled ammonia 
has been shown to be decreased49,141. Similarly, patients with dilated cardiomyopathy also 
demonstrated an abnormal coronary reserve measured by 15O-labelled water142. 
 Measurement of perfusion parameters are also typically performed in conjunction 
with cardiac metabolism imaging. Measurement of cardiac metabolic rate is typically 
achieved by 18F-2-fluoro-2-deoxy-d-glucose (18F -FDG) tracer. [18F] FDG is a glucose 
analog which is taken up by tissues such as the heart, muscle, and liver. However, [18F] 
FDG cannot be metabolized due to the hydroxyl group at 2’ position substituted with a 
radioactive isotope 18F, As a result, the measured activity of [18F] FDG is indicative of 
glucose uptake, and degree of glycolysis143. The use of [18F] FDG as indicators of tissue 
insulin sensitivity is common in clinical practice. For example a study with [18F] FDG PET 
clearly demonstrated that insulin sensitivity was highly associated with increased glucose 
uptake in the liver144,145. Furthermore, [18F] FDG PET can also be used to determine 
myocardial viability, using the criteria of low perfusion and low metabolism145,146. In 
summary, PET offers a well-established, and non-invasive method for the measurement of 
hemodynamic and metabolic parameters in the target organ. However, PET requires the 
injection of radioactive tracers, and exposure to ionizing radiation. Nonetheless, PET is an 
important imaging modality in research due to its ability to detect problems prior to actual 
onset of diseases. 
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1.4.4 Dynamic Contrast Enhanced Computed Tomography 
 
Developed in the 1970s, Dynamic Contrast Enhanced Computed Tomography 
(DCE-CT) aims to provide a non-invasive solution to the study of hemodynamics in 
tissue147. However due to limitations in spatial and temporal resolution during its infancy, 
the widespread use of DCE-CT failed to gain traction. Fortunately, over the next couple of 
decades, significant advancements in CT technology have addressed these limitations and 
propelled DCE-CT to be a competitive imaging modality with wide clinical acceptance. 
For example, development of slip-ring technology has dramatically improved temporal 
resolutions. In addition, advancements in detector technology has allowed the imaging of 
whole organs in a single study. As a result, DCE-CT has become an excellent diagnostic 
tool in the study of vascular changes, and coronary circulation associated with CVDs148–
150. In comparison to the previously mentioned modalities, DCE-CT provides a more 
complete evaluation of tissue hemodynamics with its capability to measure perfusion, 
blood volume, mean transit time, and capillary permeability surface area product in a single 
study151. In comparison to MRI, DCE-CT may appear disadvantaged due to the use of 
ionizing radiation. However, the gadolinium-based contrast agent used in contrast-
enhanced MR lacks a linear relationship between signal intensity and concentration. In 
contrast, DCE-CT provides a linear relationship between iodine contrast concentration and 
X-ray attenuation152. 
 Several studies in cardiac imaging have given solid validation to the use of DCE-
CT as a reliable diagnostic tool. One such study, recruited patients with coronary artery 
disease with varying degree of stenosis as classified from catheter-based angiograms. 
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DCE-CT with dipyridamole infusion as performed, and analyzed to calculate myocardial 
blood flow, and blood volume. The results demonstrated that blood flow is significantly 
lower in stenosed patients, and that DCE-CT appeared to be a useful predictor of 
functionally significant coronary stenosis150. In another evaluation of the use of CT 
perfusion, it demonstrated a high sensitivity and specificity in diagnosis of chest pain from 
coronary stenosis149.  
 In DCE-CT imaging, X-ray iodinated contrast agent is injected in peripheral vein, 
while the CT scanner image the passage of contrast through the myocardium. Two 
assumptions must be made in perfusion calculations: first is the uniform distribution of 
iodinated contrast through the vascular system. Second, is that the increase in attenuation 
in tissue is proportional to the concentration of contrast agent153. Typically, CT scanner 
scans the region of interest continuously for a prolonged acquisition period which captures 
the slow leakage of contrast from blood vessels into interstitial space. The algorithm used 
in DCE-CT is based on the approximation of the Johnson-Wilson model which explains 
the bidirectional exchange of contrast between the capillaries and the interstitium. This 
adiabatic approximation assumes that changes in tracer concentration are slower in 
parenchymal tissue compared to that in capillaries154. With the algorithm it is then possible 
to calculate blood flow and display the values in rainbow colored functional maps. 
 DCE-CT is an excellent imaging modality for the study of hemodynamical changes. 
It is non-invasive and widely available in hospitals, with rapid scan times. More 
importantly, it can image soft tissues, bone, and blood vessels with excellent temporal and 
spatial resolution. However, a major drawback of DCE-CT is the exposure to carcinogenic 
ionizing radiation. In addition, the injection of contrast agents which may impair renal 
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functions. Nonetheless, the use of DCE-CT may potentially provide a means to monitor 
for the onset and progression of diseases such as CVDs. 
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1.5 Research Goals 
 
The objective of this thesis was to investigate the combined effects of in utero 
insults from placental insufficiency, or high energy diets during pregnancy, combined with 
an adverse postnatal diets on the development of CVDs in early adulthood. In addition, this 
project aimed to assess the use of DCE-CT and PET in the study of CVDs in a guinea pig 
model. In this regard, the two primary goals of the thesis were as follows: 
1) Investigate the effects of placental insufficiency induced low birth weight and 
postnatal Western diet on the development of CVD in a guinea pig model with 
DCE-CT and PET imaging. 
2) Examine the effects of high energy maternal diet and postnatal Western diet on 
the development of CVD in a guinea model with DCE-CT and PET imaging.  
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Chapter 2  
 
 
 
 
2 The Impact of an Adverse In Utero Environment Resulting in Low Birth 
Weight, and a Postnatal Wester Diet on Early Development of Cardiovascular 
Diseases in Guinea Pigs 
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2.1 Introduction 
 
Cardiovascular Diseases (CVDs) are the leading causes of mortality world-wide, 
accounting for more than 17 million deaths in 2008 alone1. Characterized by cardiac 
remodeling and metabolic dysfunction processes, notable types of CVDs such as 
cardiomyopathy are typically associated with cardiac failure2–6. Traditionally, risk factors 
for CVD development are mostly attributed to life-style choices such as tobacco use, 
physical inactivity, or unhealthy dietary patterns7,8. Indeed, diets such as the increasingly 
prevalent Western Diet (WD), with its high levels of processed carbohydrates and saturated 
fatty acids, is strongly associated with an increasing risk of CVD development9,10.  
Interestingly, amounting evidence now also highlights the importance of intrauterine 
environment as a risk factor for developing chronic diseases in later life, particularly in 
cases of intrauterine growth restriction (IUGR)11. 
 IUGR is defined as the inability of the fetus to reach its expected growth potential, 
often resulting in low birth weight (LBW)12. A common cause of IUGR is placental 
insufficiency (PI), where the placenta fails to provide optimal oxygen and nutrient supply 
to the fetus13,14. Clinically, IUGR is categorized as birthweight falling below the 10th 
percentile12. However, this categorization method based on an arbitrary birthweight under-
represents newborns which lie outside the cut-off but are still exposed to the same sub-
optimal in utero environment15. For example, the development of severe adult diseases 
from in utero insults have been shown to occur independent of birthweight changes16. It is 
more likely that programming for disease development stems from a combination of in 
utero induced stress factors and an irregular developmental profile such as accelerated 
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catch-up growth in early postnatal life17,18. Of additional concern are evidence which 
highlight that in utero programmed changes can further sensitize and accelerate the 
development of CVDs from postnatal insults19. Amidst the increasing prevalence of WD, 
infants born from adverse in utero environments may become more susceptible to the 
enhanced deleterious effects of a growth restricted development profile. However our 
understanding of the relationship between prenatal and postnatal insults on offspring 
disease development has yet to be thoroughly investigated. 
  Part of this investigation is to understand the developmental progressions of CVDs 
prior to the onset of more severe consequences. Disease progression in the myocardium is 
often in concert with impairments in coronary blood flow, and metabolic alterations such 
as increased fatty acid oxidation, and cardiac insulin resistance (IR)6,20–23. Collectively, 
these are pre-clinical hallmarks of early CVD progression, and can be valuable markers for 
diagnosis. With the advancements in non-invasive imaging modalities commonly used in 
cancer diagnoses, these applications are now beginning to expand to the field of 
cardiovascular diagnoses. For example, new developments in Dynamic Contrast Enhanced 
Computed Tomography (DCE-CT) allows accessible, and non-invasive assessment of 
coronary flow and perfusion in the coronary microvasculature24,25. Additionally, Positron 
Emission Tomography (PET) has been extensively used to measure tissue specific glucose 
uptake, an indicator of IR26. These imaging modalities can prove to be valuable resources 
in identifying at risk individuals, monitoring disease progression, and potentially setting 
the stage for the development of more preventative therapies. 
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Understanding the relationship between the prevalence of CVDs and its risk factors 
is crucial in efforts to minimize harmful societal impact. The purpose of this study was to 
utilize DCE-CT and PET imaging supported by traditional molecular techniques to 
examine the developmental profile associated with early CVD development in a guinea pig 
model of in utero growth restriction and postnatal dietary insult. We postulated that 
offspring born of LBW– a marker of inadequate in utero growth – would exhibit pre-
clinical markers of cardiac dysfunction, including disruptions in basal coronary flow, and 
cardiac glucose metabolism by early adulthood. Additionally, we postulated that the 
combination of LBW and a postnatal WD would result in an accelerated advancement of 
these CVD development parameters 
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2.2 Methods 
 
2.2.1 Animals 
 
Pregnant Dunkin-Hartly guinea pigs (Charles River Laboratories, Wilmington, 
MA) were fed ad libitum guinea pig chow (LabDiet diet 5025: 27% protein, 13% fat, 60% 
carbohydrates), and housed in individual cages (20 ± 2°C, and 30-40% humidity) with a 
12 hour/light dark cycle. Uterine artery ablation (UAA) procedure was selected to impair 
placental function, fetal growth, and induce markers of CVD27,28. Briefly, all pregnant 
guinea pigs at mid gestation (~32 days) were placed in an anesthetic chamber (4-5% 
isoflurane with 2 L/min O2, and maintained at 2-3% isoflurane with 1 L/min O2) and 
immediately after induction, a subcutaneous injection of Robinul (0.01 mg/kg 
glycopyrrolate; Sandoz Canada, Montreal, QC) was administered. A midline incision was 
made below the umbilicus to expose the mesometrium of one horn of the uterus, where 
every second arterial vessel branch was cauterized using an Aaron 2250 electrosurgical 
generator (Bovie Medical, Clearwater, FL). Following surgery, a subcutaneous injection 
of Temgesic (0.025 mg/kg buprenophrine; Scherin-Plough, Kenilworth, NJ) was 
administered. Sows delivered naturally, and within 12 hours, birth weights and crown rump 
of each pup were recorded. At the end of the pupping period, guinea pig pups were defined 
as normal birth weight (NBW) if their birth weights were between 25th to 75th percentiles, 
and LBW if below the 25th percentile. Based on this criteria, and in accordance with 
previous UAA and maternal feed restriction guinea pig models,  NBW pups were 
determined to be greater than 90g, while LBW pups were determined to be below 85g29–
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31. All pups were weighed daily from birth until 15 days of age, where pups were weaned 
and randomly assigned onto either a control diet (CD) (TD: 110240, Harlan Laboratories, 
Madison WI), or a WD (TD: 110239, Harlan Laboratories, Madison WI). Both CD and 
WD contained 21% protein (% of total kcal). However, these diets differed in 
carbohydrates and fat, wherein CD contained 60% carbohydrates [distribution (% by 
weight): 35% corn starch, 10% sucrose], and 18.4% fats, while WD contained 33% 
carbohydrates [distribution (% by weight): 19% sucrose, 6.5% fructose] and 45% fats. In 
addition, composition of fats also differed, wherein CD consisted of  2.8% saturated fatty 
acids (SFA), 4.4% monounsaturated fatty acids (MUFA), and 11.2% polyunsaturated fatty 
acids (PUFA), while WD consisted of 31.7% SFA, 11.8% MUFA, 1.8% PUFA 
[distribution (% of total kcal)] (Table 2.1). In total, CD contained 3.4 kcal/g while WD 
contained 4.2 kcal/g energy. Guinea pigs were housed in individual cages at 20°C and 30-
40% humidity with 12 hour light-dark cycle. Food intake was recorded daily and body 
weights were recorded twice weekly until putdown at young adulthood (150 days). The 
resulting division in groups for the study was NBW/CD, NBW/WD, LBW/CD, and 
LBW/WD, which was further divided by sex.   
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Table 2.1 Diet Composition 
 
Diet Component Control Diet (CD) Western Diet (WD) 
Total Protein (%kcal) 22 21 
Total Fat (%kcal) 18 46 
Saturated Fatty Acids 15 70 
Polyunsaturated Fatty Acids 61 4 
Monounsaturated Fatty Acids 24 26 
Total Carbohydrate (%kcal) 60 33 
Sucrose 11 22 
Fructose - 7.6 
Cholesterol (%kcal) - 0.25 
Density (kcal/g) 3.4 4.2 
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2.2.2 Imaging 
 
Guinea pigs underwent DCE-CT and PET imaging at 50 and 110 days of life. The 
scan time point of 110 days or early adulthood was selected based on a previous study, 
which investigated IUGR/LBW associated changes in whole body glucose tolerance and 
reported alterations in offspring glucose tolerance at 101 days32. The earlier time point of 
50 days was selected to investigate possible developmental changes prior to young 
adulthood an active post weaning growth phase, as previous studies using the UAA model 
have demonstrated increased cardiac and renal fibrosis at 60 days of age28. Prior to 
scanning, baseline glucose levels were measured using a Bayer Contour glucometer (Bayer 
Diabetes, Mississauga, ON). In addition, during scanning, heart rate, respiration rate and 
arterial O2 saturation were monitored and recorded using MouseOx pulse oximeter for 
small animals (Starr Life Science Corp, Oakmont PA).  
 
2.2.3 Dynamic Contrast Enhanced Computed Tomography 
 
DCE-CT scans were performed using a clinical GE multi-slice CT scanner 
(Discovery VCT, GE Healthcare, Waukesha, Wis). Guinea pigs were anaesthetized in an 
anesthetic chamber (4-5% isoflurane with 2 L/min O2), before transferred to a tight fitting 
nose cone to maintain anesthesia with 2-3% isoflurane at a flow rate of 1 L/min.  Once 
anesthesia was stably established (absence of response to pain stimuli), guinea pigs were 
positioned in the center of the CT scanner. A scout localization scan was performed to find 
the slice locations of the heart. A two phase dynamic scan of the heart at the determined 
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slice locations was conducted following an injection of 1mL/kg of iodinated contrast 
(Omnipaque 200mgI/mL) via a pedal vein catheter at 8 mL/min. In the first phase of the 
dynamic scan, images were acquired continuously at every second for 14.6 seconds at a 
tube rotation speed of one revolution per second, voltage of 120 kV and current of 180 mA. 
This was followed by the second phase where images were acquired every 15 seconds for 
200 seconds using the same scan parameters (tube voltage, current, and rotation speed) as 
the first phase. The dynamic images were reconstructed with the GE Healthcare proprietary 
detail filter with a slice thickness of 1.25mm. The reconstructed images were transferred 
to an image processing workstation (Advantage Windows 4; GE Healthcare, Waukesha 
Wis). Using CT Perfusion 5 program (GE Healthcare, Waukesha, Wis), an arterial input 
curve of contrast medium concentration was generated with a region of interest (ROI) 
placed in the left ventricle chamber of a slice which showed the maximum size of the 
chamber. Following which, another ROI was outlined around the contour of the heart in 
the first image of the dynamic series of the same slice. Subsequent images which did not 
conform to this heart outline were removed from the study as they were mis-registered with 
the first image from either breathing or cardiac motion of the animal. Blood flow maps of 
the chosen slice were generated with the CT Perfusion 5 software (GE Healthcare, 
Waukesha, Wis.). Myocardial blood flow was calculated as the mean pixel value in a ROI 
placed in the inferior wall of the left ventricle where it is least affected by either respiratory 
or cardiac motion. 
 
2.2.4 Position Emission Tomography 
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Guinea pigs were first anaesthetized in an air-tight box with 4-5% isoflurane at 2L/min, 
and injected with ~25kBq/kg (0.2-0.3mL) of [18F]- fluoro-deoxy-glucose ([18F] FDG) via 
the pedal vein. Animals were then recovered, returned to their cage, and placed in a lead 
brick shield. Approximately 40 minutes later, they were again anaesthetized with 4-5% 
isoflurane as before, and placed on the bed of a micro-PET scanner (GE eXplore Vista DR, 
GE Healthcare, Waukesha, Wis). Anesthesia was maintained with a nose cone through 
which 2.5-3% isoflurane was flowing at the rate of 1L/min, and a 20 minute emission scan 
of the heart region was then acquired. 
After correction for scatter and random coincidences, the scan was reconstructed 
into sixty 0.78mm thick slices. The reconstructed images were analyzed using an in-house 
MATLAB program (MathWorks Inc., MA, USA). For each slice in which the left ventricle 
was visible for analysis, two ROIs were drawn: one outlining the epicardial surface, and 
the other one the endocardial surface of the left ventricle. The difference in the total counts 
was divided by the difference in volume of the ROIs to arrive at the average count in the 
myocardium. This average was converted to activity (Bq) using a sensitivity calibration 
factor determined from routine quality assurance of the scanner. The image derived 
activities from all LV slices were averaged together to calculate myocardial activity. 
Standardized Uptake Value (SUV) in the left ventricular myocardium was calculated as: 
 
𝑆𝑈𝑉 =
𝑀𝑦𝑜𝑐𝑎𝑟𝑑𝑖𝑎𝑙 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦
𝐼𝑛𝑗𝑒𝑐𝑡𝑒𝑑 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝐵𝑜𝑑𝑦 𝑊𝑒𝑖𝑔ℎ𝑡⁄
                                                              (1) 
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2.2.5 Tissue Collection 
 
Following a recovery period after the 110 day scan, at postnatal day 143±1.9, 
animals were sacrificed by CO2 inhalation following an overnight fast
33. The heart was 
removed, trimmed of connective tissue, weighed, and carefully separated into left or right 
ventricles. A coronal cross section above the apex of the left ventricle of approximately 
3mm thick was placed in 4% paraformaldehyde for histological analyses34. The remainder 
of the left ventricle was frozen in liquid nitrogen for RNA and protein analysis.  
 
2.2.6 Quantitative Real-Time PCR 
 
Flash frozen left ventricular tissues were homogenized in Trizol® (Invitrogen Life 
Technologies Co., Burlington, ON), followed by 200 µL of chloroform for each tissue 
sample. The mixed solution was centrifuged at 12,000g for 15 minutes at 4°C. The resulting 
aqueous phase was transferred to new RNAse-free tubes, and 500 µL of isopropyl alcohol 
was added. The new solution was centrifuged at 12,000g for 10 minutes at 4°C to obtain 
RNA precipitate. Following three 75% ethanol washes at 7500g for 5 minutes, the RNA 
pellet was reconstituted in RNAase free diethylpyrocarbonate water. Yield and quality 
(A260/A280 ration) of RNA was determined with NanoDrop 2000 UV-Vis 
Spectrophotometer (Thermo Scientific, Waltham MA, US). Isolated RNA (4µg) were 
reverse transcribed into complementary DNA with M-MLV Reverse Transcriptase 
(Invitrogen Life Technologies Co., Burlington ON). Real-time qPCR was performed for 
each sample in duplicate and was completed using a Bio-Rad CFX384 real time PCR 
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detector (Bio-Rad Laboratories Mississauga, ON) at a denaturing temperature of 95°C, 
annealing temperature of 59.5°C, and elongation temperature of 72°C for 39 cycles. Data 
are presented as a fold change in expression compared to NBW/CD exposed animals. The 
2-ΔCT method with β-Actin as housekeeping gene was used for analysis35. Primer sets are 
listed in Appendix A. 
 
2.2.7 Western Blot 
 
Flash frozen left ventricular tissues were pulverized and homogenized in RIPA lysis 
buffer (50 mM Tris-HCl, NP-40 1%, Na-deoxycholate 0.25%, 1mM EDTA, 150 mM 
NaCl,  50 mM NAF, 1mM NaV, 25 mM β-glycerophosphate, pH 7.4) with protease and 
phosphatase inhibitor. Homogenates were centrifuged at 10,000g for 15 minutes at 4°C. 
Supernatants were transferred to fresh tubes and used as protein preparations, which were 
quantified with DC™ Protein Assay Kit (Bio-Rad Laboratories, Mississauga, ON). 
Loading samples of 30 µg protein were then separated by size on 6% Bis-Tris gels, and 
transferred on to nitrocellulose membranes for an overnight block with 5% bovine serum 
albumin at 4°C. Blots were then probed with AKT-1 (Cell Signaling® #4691, 1:1000), 
pAKT Serine 473 (Cell Signaling® #9271, 1:1000), pAKT Threonine 308 (Cell 
Signaling® #9275, 1:1000), and monoclonal horseradish peroxidase-conjugated β-actin 
Sigma-Aldrich #A3854, 1:50000) diluted in 5% bovine serum albumin in Tris-buffered 
saline/Tween 20 (0.01%) for 1 hour at room temperature. Blots were then probed with 
horseradish peroxidase conjugated goat anti-rabbit IgG (Cell Signaling® #7074, 1:1000) 
secondary antibody diluted in 5% bovine serum albumin in Tris-buffered saline/Tween 20 
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(0.01%) for 1 hour at room temperature.  Immunoreactive bands were detected using 
Luminata Forte Western HRP Substrate chemi-luminescence (EMD Millipore, Darmstadt, 
Germany), and imaged with VersaDoc Imaging System (Bio-Rad Laboratories 
Mississauga, ON). Densitometry values (arbitrary units) were determined using the 
ImageLab software (Bio-Rad Laboratories, Mississauga, ON), and the abundance of 
proteins were expressed relative to β-Actin. 
 
2.2.8 Histological Analysis 
 
Immediately following putdown, coronal cross-sections of the guinea pig left 
ventricles were collected in 4% paraformaldehyde, embedded in paraffin, and then sliced 
in 5µm sections. Paraffin-embedded sections were stained with hematoxylin and eosin 
(H&E) or Masson’s trichrome for histological analysis of hypertrophy, inflammation and 
fibrosis. Eight non-overlapping colored images of the H&E stained slides were obtained at 
200x magnification using Leica DMI 6000B microscope (Leica Microsystems, Wetzlar, 
Germany). Utilizing Leica MMAF software (v1.40, Leica Microsystems, Wetzlar, 
Germany), cardiomyocytes with visible nuclei was outlined in each of the eight non-
overlapping images. The cardiomyocyte cross sectional area were calculated in square 
micrometers, and averaged between the non-overlapping images as per previous studies on 
cardiac hypertrophy36. Similarly, eight non-overlapping colored images of the Masson’s 
trichrome stained sections were obtained at 100x magnification. Again, utilizing the Leica 
MMAF program, areas of the blue stained collagen fields were measured and divided by 
the total area of the field, omitting the voids36,37.  The collagen fractions of each section 
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were then expressed as the mean percentage of collagen. Analysis of the histological 
sections were performed under blinded conditions. 
 
2.2.9 Statistical Analysis 
 
Statistical Analysis was performed with SPSS software (SPSS v22.0, Chicago, IL, 
USA). A mixed model ANOVA analysis was used to determine significant differences 
(p<0.05) from sex, age, birth weight, and postnatal diet. If significant differences or 
interactions were determined, student t-tests were used for post-hoc analyses of differences 
between groups. 
  
60 
 
2.3 Results 
 
2.3.1 Birthweight and Development 
 
Clinically, determination of growth restriction is arbitrary assigned based on 
measurement of birth weight (<10th percentile)38. Similarly, this study categorized LBW, a 
proxy for growth restriction, as offspring whose birthweight fell below the 25th percentile 
of mean birth weights. As a result, pups which were categorized as LBW were 29% lighter 
at birth compared to those which were categorized as NBW, independent of sex (Figure 
2.1, p<0.05). In addition, at birth these LBW offspring displayed a lower Weight/Length 
ratio, a measure of leanness (Figure 2.1, p<0.05), which have been previously observed in 
other models of IUGR32.  By putdown at 143±1.9 days, these LBW offspring displayed 
similar body weights to that of the NBW group, however, females demonstrated a diet 
induced reduction in bodyweight (Figure 2.2, p<0.05). Moreover, heart weight relative to 
body weight was not significantly altered between groups (Figure 2.2). 
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Figure 2.1 Characteristics at Birth. Pups were categorized as LBW group based on a 
pre-established cut-off determined as below the 25th percentile of average birth weights. 
Birth weight of A) female, B) male guinea pig pups were recorded. N=18 (NBW), N=11 
(LBW) in females, and N=13 (NBW), N=13 (LBW) in males.  In addition, ratio of birth 
weight over crown rump length of C) female, and D) male guinea pig pups was determined. 
N=13 (NBW), N=8 (LBW) in females, and N=12 (NBW), N=10 (LBW) in males.  
*p<0.05. Box represents Mean and SEM, while whiskers represents Max and Min values. 
Statistical significance was determined by student’s t-test. 
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Figure 2.2 Putdown Characteristics. Bodyweights of A) female and B) male guinea pigs. 
Percent ratio of heart weight relative to body weight at of C) female and D) males at day 
143 ± 1.9. N=8 (NBW/CD), 10 (NBW/WD), 5 (LBW/CD), 6 (LBW/WD) for females. N=6 
(NBW/CD), 7 (NBW/WD), 6 (LBW/CD), 7 (LBW/WD) for males. *p<0.05. Box 
represents Mean and SEM, while whiskers represents Max and Min values. Statistical 
analysis performed by two-way ANOVA. 
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2.3.2 LBW Resulted in Reduction in Basal Coronary Blood Flow in Young Adulthood 
 
Following a 2 hour fast, and just prior to DCE-CT and PET scanning, animals from 
all four treatment groups, displayed a similar glucose level of 9.1 ± 0.4 mmol/L. During 
scanning, the animals maintained an average heart rate of 205±24 bmp, and an average 
oxygen saturation above 98%. No significant deviations in these physical parameters were 
observed during the 40 minute scan period (Table 2.2). 
Coronary vascular dysfunction often occurs with the increasing severity of cardiac 
hypertrophy, and cardiomyopathy20,39,40. More importantly, alterations in coronary flow 
and microvasculature precedes heart failure, and is known to be a strong predictor of 
hypertrophic cardiomyopathy41. Using DCE-CT, basal coronary flow in the inferior wall 
of the left ventricle was determined at 50 and 110 days. A significant birthweight and age 
interaction was observed, where coronary flow of LBW guinea pigs was reduced by 17% 
compared to NBW as they reach adulthood (Figure 2.3, p<0.05). In comparison, NBW 
animals demonstrated a 10% increase in coronary blood flow as they reach adulthood.  
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Table 2.2 Baseline Physiological Parameters during Scanning Procedures. Average 
baseline readings of glucose, heart rate, and oxygen saturation during CT and PET scanning 
at (A) 50 days, and (B) 110 days.  Data presented as mean ± standard error. N=12 
(NBW/CD), 14 (NBW/WD), 7 (LBW/CD), 6 (LBW/WD) for females. N=9 (NBW/CD), 9 
(NBW/WD), 5 (LBW/CD), 3 (LBW/WD) for males. Statistical significance examined by 
two-way ANOVA. 
Sex BW Diet Glucose 
Heart Rate 
(bpm) 
O2 Saturation (%) 
Female NBW CD 9.33±1.05 243.6±9.7 98.4±0.9 
  WD 9.85±0.91 232.9±7.9 97.7±0.7 
 LBW CD 8.02±1.29 250.1±9.7 97.6±0.9 
  WD 8.45±1.82 234.7±13.7 97.6±1.2 
Male NBW CD 10.56±0.86 228.9±9.0 98.4±0.8 
  WD 8.80±0.97 261.0±9.7 96.9±0.9 
 LBW CD 10.64±1.15 220.9±9.0 97.7±0.8 
  WD 8.40±1.29 235.5±10.6 96.8±0.9 
  Significance ns ns ns 
      
 
 
     
Sex BW Diet Glucose 
Heart Rate 
(bpm) 
O2 Saturation (%) 
Female NBW CD 8.83±0.92 223.6±10.7 96.1±1.2 
  WD 8.35±0.58 217.9±6.8 98.0±0.7 
 LBW CD 9.97±0.70 235.1±8.1 97.6±0.9 
  WD 8.73±0.92 207.4±10.7 97.8±1.2 
Male NBW CD 9.12±0.53 228.2±6.2 99.0±0.7 
  WD 8.25±0.75 224.3±8.8 99.2±1.0 
 LBW CD 9.80±0.83 234.1±9.6 98.4±1.0 
  WD 8.65±0.92 223.6±9.6 97.6±1.0 
  Significance ns ns ns 
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Figure 2.3 Basal Coronary Blood Flow Determined by DCE-CT.  A) Color coded blood 
flow maps were calculated from DCE-CT, where cool colors represent areas of low blood 
flow, while warm colors represent areas of high blood flow. B) Mean coronary blood flow 
in the inferior wall of left ventricle at 50 and 110 days of post-natal life determined by CT 
Perfusion software (GE Healthcare, Waukesha, Wis). *p<0.05 Interaction.  N= 27 and 30 
for 50 day old guinea pigs of NBW and LBW respectively, and N=18 and 22 for 110 day 
old guinea pigs of NBW and LBW respectively. A repeated measures three-way ANOVA 
was used to determine statistical significance. ANOVA table presented in Appendix C. 
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2.3.3 WD Consumption Reduced Basal Glucose Uptake by Adulthood 
 
In the development phase of many CVDs, the cardiac metabolic profile is often 
altered, resulting in a state of IR42,43. Specifically, a switch in favor of fatty acid oxidation 
was believed to be a protective mechanism against heart failure44. As a result, changes in 
glucose metabolism, a proxy for determining IR, is a useful pre-clinical marker for diseases 
such as hypertrophic cardiomyopathy. 
Determination of basal cardiac glucose uptake at 50 and 110 days was completed 
using [18F] FDG -PET. Where, chronic postnatal WD consumption resulted in a 21% 
reduction in glucose uptake compared to CD groups at both time points (Figure 2.4, 
p<0.05). No alterations in glucose uptake were influenced by birthweight.    
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Figure 2.4 Cardiac Glucose Uptake Determined by PET. A) Color coded image of F-
18 fluorodeoxyglucose ([18F] FDG) uptake determined by PET, where areas of warm colors 
describe the intensity of [18F] FDG uptake. Standardized uptake value (SUV), a semi-
quantitative index of [18F] FDG uptake, and insulin sensitivity, was determined in the left 
ventricle by defining a region of interest around the left ventricle. B) SUV of CD and WD 
animals at both 50 and 110 day time points. N = 27 for CD fed animals and N=22 for WD 
fed animals. *p<0.05. Box represents Mean and SEM, while whiskers represents Max and 
Min values. A repeated measures three-way ANOVA was used to determine statistical 
significance. ANOVA table presented in Appendix D. 
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2.3.4 Cardiac Remodeling and Collagen Content Were Increased in LBW Offspring 
 
Inadequate cardiac development, which is likely the result of adverse in utero 
environments, combined with an accelerated growth profile may trigger the hypertrophic 
growth of cardiomyocytes and proliferation of non-myocytes such as fibroblasts, therefore 
setting the stage for pathological hypertrophy45,46. These cardiac remodeling processes are 
crucial components in the eventual development of systolic dysfunction, and are strongly 
associated with alterations in coronary circulation40. Following putdown, cross-sections of 
left ventricles were analyzed for histological markers of hypertrophy and fibrosis. Heart 
sections from LBW offspring displayed a 20% increase in cardiomyocyte cross-sectional 
area compared to NBW offspring (Figure 2.5, p<0.05), indicative of a hypertrophic growth 
phenotype.  
 
2.3.5 Expressions of Collagen Increased in LBW Females 
 
Enlargements in cardiomyocytes can be attributed to both classifications of cardiac 
hypertrophy, which is physiological or pathological. However, pathological hypertrophy 
differs in that it is characterized by fibrosis, particularly an excessive expression of 
collagen47,48. In the LBW, and NBW/WD sections, a 1.9 fold increase in collagen 
composition compared to NBW/CD sections was recorded, therefore highly suggestive of 
a pathological hypertrophy phenotype (Figure 2.6, p<0.05).  
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Additionally, the mRNA expression of pro-fibrotic genes as α smooth muscle actin 
(α-SMA), Type 1 and 3 collagen, matrix metalloproteinase-1 (MMP1) and transforming 
growth factor β (TGF-β) was determined (Table 2.3). These genes are known to play 
important roles in the tissue fibrosis pathway49. A significant sex and birth weight 
interaction for type 1 collagen mRNA was observed, where female LBW animals 
demonstrated a significantly higher expression than NBW females (Figure 2.7, p<0.05). 
The expression of the other targets, α-SMA, type 3 collagen, MMP1, and TGF-β were 
consistent across sex, BW, and diet. 
 
2.3.6 WD Feeding is Associated with a Reduction in AKT Activation 
 
One of the main markers of CVD development is cardiac IR, an observation 
reported in conjunction with WD consumption50,51. Specifically, the disruption of kinases 
in the insulin stimulated glucose uptake pathway, such as insulin receptor substrate (IRS), 
and Protein Kinase B (AKT), is an important marker behind tissue specific IR44,52,53. Other 
reports in skeletal muscle also reported reductions in AKT activation, specifically 
Threonine 308 (T308)  and Serine 473 (S473), was strongly associated with growth 
restriction54–56. In the current study, despite no alterations in pIRS protein expression, 
pAKT (T308) to total AKT-1 was significantly reduced in female WD fed guinea pigs 
(Figure 2.8, p<0.05), whereas males appeared to be unaffected by diet. Furthermore, 
birthweight appeared to not confer any adverse impact in both sexes. 
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Figure 2.5 Cross-Sectional Area of Cardiomyocytes.  A) Hematoxylin and Eosin stained 
cross-sectional histological sections of left ventricles at putdown. Average cross-sectional 
area (µm2) of cardiomyocytes in the left ventricle was determined between multiple 
representative slides. White scale bar in representative images indicate 25 µm length. B) 
Cardiomyocyte cross-sectional area between NBW and LBW animals. *p<0.05. N=15 for 
NBW and N=13 for LBW animals. Box represents Mean and SEM, while whiskers 
represents Max and Min values. Statistical significance was determined by a two-way 
ANOVA. ANOVA table presented in Appendix E. 
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Figure 2.6 Collagen Content in the Left Ventricle A) Trichrome stained histological 
sections of left ventricle. Average area (µm2) of blue shaded collagen deposition was 
determined as an indicator of fibrotic growth. White scale bar in representative images 
indicate 100 µm length. B) % of Collagen deposition. *p<0.05 Interaction. N=8 for both CD 
and WD fed NBW guinea pigs, and N=4 and 6 for CD and WD fed LBW guinea pigs, 
respectively. Data presented as Mean ± SEM.  Statistical differences determined by two-way 
ANOVA. ANOVA table presented in Appendix F. 
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Table 2.3 Relative mRNA Expression of Fibrotic Genes. Relative mRNA expression of 
αSMA, Type 3 collagen, MMP-1, and TGFβ to Female NBW-CD group. No significant 
differences were observed in the mRNA expression of these genes. N= 4 for NBW/CD, 
NBW/WD, LBW/CD and LBW/WD in each sex. Statistical analysis completed by two-
way ANOVA. 
 
 
Sex BW Diet αSMA 
Type 3 
Collagen 
MMP-1 TGFβ 
Female NBW CD 1 1 1 1 
  WD 1.07 1.13 0.98 0.66 
 LBW CD 1.12 1.49 0.8 0.87 
  WD 0.78 1.19 0.77 0.85 
Male NBW CD 0.71 0.99 0.89 0.66 
  WD 0.36 1.62 0.91 1.05 
 LBW CD 0.43 1.33 1.13 1.02 
  WD 0.79 1.19 1.18 1.32 
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Figure 2.7 Type 1 Collagen mRNA Expression. Relative mRNA expression of Type 1 
Collagen in the left ventricle at 140 ± 1.9 day putdown. *p<0.05 Interaction. N= 4 for 
NBW/CD, NBW/WD, LBW/CD and LBW/WD in each sex. Data presented as Mean ± 
SEM. Statistical significance determined by two-way ANOVA. ANOVA table presented 
in Appendix G. 
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Figure 2.8 AKT Expression in the Left Ventricle at Putdown. Expression of pAKT 
(T308) relative to total AKT-1 protein in the left ventricle at 140 ± 1.9 days of age. *p<0.05 
Interaction. N= 4 for NBW/CD, NBW/WD, LBW/CD, and LBW/WD in both males and 
females. Data presented as Mean ± SEM. Statistical significance determined by two-way 
ANOVA. ANOVA table presented in Appendix H, 
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2.4 Discussion 
 
Adverse in utero environments such as PI are known risk factors for the 
development of heart diseases in later life. Abnormal cardiac development processes which 
result from growth restricted pregnancies are believed to underlie the development of 
myocardial complications in later life34.  Similarly, postnatal WD consumption is also 
known to result in CVD development, including the onset of cardiac IR, and eventually, 
cardiac dysfunction9,57. It can be inferred from these individual findings that the 
predisposition of CVDs from in utero factors can further increase an individual’s 
susceptibility to a secondary postnatal insult such as WD consumption. This study intended 
to elucidate the independent and combined effects of LBW and WD on early markers of 
impaired cardiac function in a guinea pig model. The principle findings of this study were 
that 1) an adverse in utero environment resulting in LBW was associated with reduction in 
resting coronary blood flow and the onset of pathological hypertrophy, and 2) postnatal 
WD consumption resulted in reduced cardiac glucose uptake. Together, these findings in 
early adulthood demonstrated that following an adverse in utero environment and a poor 
postnatal diet, key pre-clinical markers of CVDs are present. Given that these early markers 
are associated with severe cardiac dysfunction in later life, the current experiment 
highlights an early stage of disease development that may serve as a platform from which 
to undertake early intervention therapies. 
 The guinea pig was selected as an animal model in this study due to its similarities 
to humans with respect to in utero developmental programming. Unlike other rodents, 
guinea pigs are prenatal organ developers, where pups are mature at birth58,59. For this 
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reason, the guinea pig fetus is particularly vulnerable to influences in placental function 
such as the UAA procedure, PI (where reduction in oxygen and nutrient delivery typically 
results in growth restriction), and LBW13,60–62. As a result, not only are the birth weights 
of LBW categorized offspring reduced, but body composition is also altered, as evident by 
the reduction in weight/length ratio32,62. An in utero insult such as UAA likely impacts 
genetically determined growth differentially. Yet, during post-natal life, a reversal of this 
delayed growth trajectory was observed in LBW offspring, where, by young adulthood, 
LBW body weights were similar to the NBW group. This pattern of rapid catch-up growth 
is a known consequence of asymmetrical growth restriction63,64. More importantly, this 
accelerated growth trajectory during the critical postnatal developmental periods have been 
implicated in metabolic and endothelial impairments, as well as the development of chronic 
diseases such as adulthood diabetes and CVDs29,65,66. 
CVDs such as cardiomyopathy are often accompanied by the development of 
cardiac hypertrophy. This hypertrophic phenotype is an important marker of deteriorating 
cardiac health, and eventually, heart failure4,67. Interestingly, during critical periods of 
cardiac disease progression, disturbances in coronary flow can also occur. For example, up 
to a 16% reduction in basal coronary blood flow have been observed in patients with 
hypertrophic cardiomyopathy20,21. Therefore, we regarded these parameters as essential 
clues in recognizing early changes to cardiac health, and valuable predictors of systolic 
dysfunction and cardiomyopathy47. Utilizing DCE-CT, we observed that LBW offspring 
had a 17% reduction in basal coronary flow compared to the NBW group at 110 days of 
age. This reduction in coronary flow may reflect disturbances in myocardial capillaries, 
and microvasculature, which are the main determinants of coronary blood flow. It has been 
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previously reported that during pathological hypertrophy, capillary density in the left 
ventricle is greatly reduced47. This led us to speculate that LBW may be a major risk factor 
for CVD development in adulthood via hypertrophic and fibrotic processes. Indeed, by 
putdown, histological analyses revealed that the average cardiomyocyte size in LBW 
animals were significantly increased compared to NBW animals. Furthermore, LBW 
animals also displayed a higher percentage of collagen composition independent of sex, 
and an increased mRNA expression of type 1 collagen in females. The enlargement in 
cardiomyocytes and the abundance of collagen are hallmarks of a pathological hypertrophy 
phenotype, and supports our speculation that reductions in coronary flow determined by 
DCE-CT maybe a reflection of its development.  
This apparent prenatal programming of cardiac remodeling may have emerged 
from the hindered development of cardiomyocytes in utero. A reduction in cardiomyocyte 
numbers has been identified as a major consequence of an insufficient in utero 
environment, and since proliferation of cardiomyocytes halts in the postnatal period, the 
demand for postnatal cardiac growth is therefore fulfilled by hypertrophic growth68,69. 
Furthermore, remodeling of the developing heart may be driven by increased vascular bed 
resistance in LBW offspring in utero, resulting in an increased mechanical force for 
ejection70,71. This chronic increase in ventricular load has been shown to trigger cardiac 
remodeling processes that underlie the development of pathological hypertrophy early in 
adolescence 71,72. Together, these underlying factors can be further aggravated by the 
increasing demand for growth in a rapid post-natal growth profile, and as a result, rapid 
development of CVD may occur. Growth restricted pregnancies have been documented to 
result in increased ventricular diameter, intima-media thickness, and altered ventricular 
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shape in children, all indications of an early hypertrophic phenotype73. Altogether, these 
results suggests that an adverse in utero environment characterized by insufficient supply 
of oxygen and nutrition to meet the adequate growth potential during pregnancy, combined 
with the postnatal pressures of catch-up growth underlies the development of pathological 
hypertrophy. This in utero programmed alteration in cardiac physiology may very well be 
responsible for the vulnerability of LBW offspring to CVD development in later life.  
Diets such as the WD during postnatal life can also have major consequences in 
cardiac health. Long term consumption of a WD is associated with diabetes, hypertension, 
and heart failure 9,57. While these gross abnormalities develop over the course of adulthood, 
tissue specific alterations in metabolism develop prior to whole body expression of the 
disease states. For example, cardiac IR has been shown to occur prior to that of whole body 
IR and more importantly, prior to cardiovascular dysfunction6,44,50. Interestingly, we have 
seen that both LBW and postnatal high fat/sugar diet exposure are required to unmask the 
consequential effects on glucose homeostasis, and insulin signaling19. Therefore, we 
suspect that WD consumption and cardiac IR can exacerbate the consequences of prenatal 
programming of CVDs. Despite normal whole body glucose tolerance (K. Dunlop, per 
comms), cardiac PET scan demonstrated that WD consumption was associated with a 
reduction in basal glucose uptake in the left ventricle, independent of BW. Additionally, 
postnatal WD feeding was associated with a reduction in AKT-1 T308 phosphorylation, 
with a higher magnitude of reduction in females, despite no changes in AKT-1 S473 
phosphorylation. Activation of AKT is an important step in the insulin mediated glucose 
uptake pathway, and is normally represented by phosphorylation at both S473 and T30874. 
However, reports have suggested that the activity of AKT is more closely correlated with 
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T308 phosphorylation, and that concurrent inhibition at both sites is not required for 
depression in insulin signaling75–77. This suggests the possibility that glucose transport and 
uptake in the left ventricle may have been suppressed by WD consumption via the 
inhibition of T308 phosphorylation of AKT-1. Together, these findings suggests that WD 
plays a prominent role in the onset of cardiac IR through disruptions in the insulin signaling 
pathway. Interestingly, we suspect that the onset of cardiac IR is an early protective 
mechanism against cardiac dysfunction. This same idea was also advocated by a study 
which demonstrated preserved cardiac functions in insulin resistant high-fat diet fed rats44. 
However, with time, a more advanced stage of the disease can unfold, where fatty acid 
oxidation –  the primary energy source in cardiac metabolism – is disrupted, and may lead 
to severe cardiovascular dysfunction78,79. In further support, high-fat diet studies have also 
demonstrated that fatty acid oxidation was increased in an early non-hypertrophied 
myocardium, but maladapted in a hypertrophied myocardium10,80.  Based on these reports, 
the diet dependent depression in basal glucose uptake observed in this study suggests that 
these animals are in an early stage of CVD progression, with the potential for more severe 
cardiovascular related consequences in later life.  
Interestingly, WD fed NBW animals also demonstrated high amounts of collagen 
in the left ventricle, similar to the levels measured in LBW animals. This is likely the result 
of excessive accumulation of ROS from saturated fatty acids present in the WD, which is 
linked to extracellular matrix remodeling and fibrosis 79,78. However, since LBW and WD 
consumption individually resulted in similar levels of collagen content, this implied that 
the combination of LBW and WD did not result in an additive relationship at the age 
studied. Similarly, our group’s previous study also discovered that endothelial dependent 
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relaxation was blunted in LBW offspring, but again not affected by the secondary insult 
from WD29.  However, other studies have proposed that IUGR could enhance the harmful 
metabolic responses to a high fat diet through IR and adipocyte dysfunctions81. Perhaps the 
in utero enhancements of diet induced CVD development processes requires a longer 
manifestation period. Thus, further studies on long term impact should be conducted. 
Nonetheless, it is clear that the consequences from WD consumption may not be 
manifested as rapidly as in utero insults, and may also occur in a different manner. For 
example, hypertrophic growth and fibrosis in LBW offspring may have arisen from chronic 
increases in vascular bed resistance in utero combined with pressures from rapid postnatal 
growth. Meanwhile, consumption of WD is associated with cardiac IR, with multiple 
proposed underlying mechanisms, including adipocyte dysfunction, inflammation, and 
release of fatty acid metabolites19,82,83. Despite the disassociation between LBW and WD 
effects in our study, other reports have demonstrated that growth restricted fetuses are 
linked to the development of IR in adulthood. Specifically, during growth restriction, the 
limited supply of glucose can lead to the shutdown of the Insulin like Growth Factor (IGF) 
system84. However during postnatal life, the abundance in nutrients, and demand for catch-
up growth results in excessive increases in insulin production, and activation of IGF system 
and insulin-like actions, which ultimately, results in adult IR85. Therefore, given that LBW 
and WD insults share similar cardiovascular consequences, we expect that with age, these 
common consequences of LBW and postnatal WD such as IR and fibrosis will become 
exacerbated.  
 The consequences of poor in utero growth and poor postnatal diets have been 
widely accepted to play critical independent roles in the later life development of CVDs. 
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Recent work is now beginning to unravel the complex interactions in CVD development 
when both these situations occur concurrently. In this current report, we used DCE-CT to 
report reductions in coronary blood flow at young adulthood associated with LBW. In 
support, molecular results also indicated evidence of cardiac hypertrophy, which likely 
contributes to the alterations in blood flow. These findings suggests that abnormal cardiac 
development processes at birth may arise from environmental pressures during pregnancy. 
This manifests in postnatal life, resulting in the development of key pre-clinical markers of 
CVDs. Additionally, the use of PET imaging also highlighted an early indication of altered 
cardiac insulin sensitivity, though it was only associated with WD consumption following 
weaning. Alterations in cardiac glucose uptake, or insulin sensitivity is also a strong early 
indicator of many CVDs, where by young adulthood, WD fed offspring, irrespective of 
birthweight, were significantly impacted. Despite the healthy, non-obese, glucose tolerant 
phenotype (K. Dunlop, per comms), these changes in the cardiovascular system exposes 
the underlying development of severe CVDs. Furthermore, since in utero predisposition 
and WD consumption share common consequences such as early indication of cardiac 
fibrosis and IR development, we believe that with time, the exacerbated effects of these 
two insults will become more apparent. In summary, this study used non-invasive, novel 
imaging techniques to detect specific early markers of CVDs, and highlights the need for 
additional long term studies on the combined effects of in utero and postnatal insult. 
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Chapter 3  
 
3 The Impact of an Adverse Maternal Diet Prior to and During Pregnancy Upon 
Young Guinea Pigs Fed a Postnatal Western Diet on the Early Development 
of Cardiovascular Diseases. 
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3.1 Introduction 
 
 
Development of cardiovascular diseases (CVD) are typically associated with 
unhealthy lifestyle choices such as physical inactivity, smoking, and the consumption of 
Westernized Diets (WD)1,2. As the highest cause of mortality in the developed world, 
CVDs like cardiomyopathy are a major risk factor to our society. That is before taking into 
account the recent revelations in perinatal research, which highlights the contributions of 
adverse fetal programming on the development of chronic diseases in adultood3. This 
concept of prenatal stress as origins of CVDs and its markers such as myocardial insulin 
resistance (IR), and left ventricular hypertrophy have been coined “fetal programming”4–6. 
Indeed, previous studies have demonstrated that maternal WD consumption during 
pregnancy was associated with a higher risk for developing growth restriction, LBW and 
later life chronic diseases in the offspring6–8. Similarly, our previous findings also 
demonstrated that postnatal WD feeding could result in disruptions in myocardial glucose 
uptake - a sign of IR, and deteriorating cardiac health. Conceivably, the consumption of a 
WD during pregnancy may also deny the developing fetus the necessary dietary and 
nutritional requirements, therefore providing another means of developing later life 
diseases. Compelling evidence have strongly advocated that ongoing consumption of 
unhealthy diets in pregnancy and in postnatal life, can further hasten or exacerbate the 
progression of chronic diseases in adult life5,6,9,10.  
Studies have demonstrated that the onset of severe cardiovascular consequences 
such as cardiac dysfunction could result from in utero and postnatal dietary insults11–13. 
However, these end-point studies represents a mature disease state, and hence miss the 
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preclinical developmental markers which precedes them. For example, the development of 
cardiac dysfunction resulting from severe CVDs are often preceded by cardiac remodeling 
processes including hypertrophy, and fibrosis in the myocardium14,15. This onset of 
pathological hypertrophy occurs in conjunction with a reduction in capillary density, which 
is strongly associated with alterations in coronary blood circulation and cardiomyocyte 
hypoxia16. Furthermore, reductions in coronary flow reserve – the ratio of stress to basal 
coronary flow – which precedes the onset CVDs is an effective pre-clinical indicator of 
heart failure17–20.  From a clinical perspective, techniques which can non-invasively 
visualize these pre-clinical parameters and predicate later life CVD development are highly 
important. An effective predictor of long-term atherosclerotic disease progression appears 
to be coronary endothelial and flow function18. However, traditional methods in measuring  
coronary flow often requires invasive catheterization21, while molecular studies in animals 
again only provides end point results. In the previous chapter, we have demonstrated the 
potential of non-invasive imaging in cardiovascular research, therefore we again proposed 
the use of Dynamic Contrast Enhanced Computed Tomography (DCE-CT) and Positron 
Emission Tomography (PET) as early detection methods of compromised coronary blood 
flow and cardiac glucose uptake respectively.  
The purpose of this study was to determine whether the consequences of dietary 
insult, through all life exposure, and during pregnancy is translated to the next generation. 
Specifically, we aimed to investigate if these insults would result in the onset of preclinical 
markers of CVDs in the offspring by adulthood. We postulated that maternal WD 
consumption prior to and during pregnancy and lactation, combined with offspring 
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postnatal WD consumption would result in alterations in coronary blood flow, and cardiac 
glucose uptake, both early markers of CVDs, in adulthood. 
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3.2 Methods 
 
3.2.1 Animal Model 
 
This study utilized female Dunkin-Hartly guinea pigs (Charles River Laboratories, 
Wilmington, MA) which were fed ad libitum from weaning to either a control diet (CD) 
(TD:110240, Harlan Laboratories, Madison WI), or a Western Diet (WD) (TD:110239, 
Harlan Laboratories, Madison WI) (See Table 2.1). Guinea pigs were housed individually 
at 19°C and 30% humidity with 12 hour light-dark cycle. These female guinea pigs were 
allowed to breed with male guinea pigs that were fed ad libitum to guinea pig chow 
(LabDiet diet 5025: 27% protein, 13% fat, 60% carbohydrates). Sows delivered naturally, 
and birth weights of each pup were recorded. Subsequently, these pups were weaned at 15 
days of age, and randomly assigned onto either a CD or WD, which formed the four 
treatment groups of Maternal CD/ Postnatal CD (MC/CD), Maternal CD/ Postnatal WD 
(MC/WD), Maternal WD/ Postnatal CD (MW/CD), and Maternal WD/ Postnatal WD 
(MW/WD). Pups were weighed twice a week, and feed intake determined daily out to study 
endpoint. 
 
3.2.2 Imaging 
 
Previously, a study had reported that alternations in glucose tolerance associated 
with in utero insults occurred at approximately 101 days in a guinea pig model22. Similarly, 
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we selected the 110 day as a representative time point at young adulthood to investigate 
cardiac health. Additionally, another study also reported onset of IR at 210 days following 
high fat diet introduction23. Therefore, a 210 day time point was also selected to investigate 
changes which may develop later in adulthood. At the chosen 110 and 210 days of postnatal 
life, guinea pigs underwent DCE-CT and PET|. Induction of anesthesia was performed in 
an air tight chamber, through which 4-5% isoflurane was administered at a rate of 2L/min. 
During both DCE-CT and PET scanning, anesthesia was maintained with a tight fitting 
nose cone with 2-3% isoflurane flowing at a rate of 1L/min 
 
3.2.3 Dynamic Contrast Enhanced Computed Tomography (DCE-CT) 
 
This study utilized a GE Healthcare multi-slice CT system (Discovery VCT, GE 
Healthcare). Guinea pigs were positioned in the center of the CT scanner. To measure 
baseline coronary flow levels, a two phase DCE-CT scan was conducted following an 
intravenous injection of 1ml/kg of iodinated contrast (Omnipaque 200mgI/mL) via a pedal 
vein catheter at 8 ml/min. In the first phase of the scan, images were acquired continuously 
every second for 14.6 seconds. This was immediately followed by the second phase, where 
images were acquired every 15 seconds for 200 seconds. For both phases, images were 
acquired at a tube voltage of 120 kV, current of 180 mA, and a rotation speed of one 
revolution per second. Ten minutes following baseline data acquisition, hyperaemic blood 
flow was also recorded by induced cardiac stress. Briefly, dipyridamole (DIP, 0.56mg/kg) 
was injected at 0.142 mg/kg of body weight/ minute over four minutes, and a two phase 
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DCE-CT scan, similar to the one at baseline was repeated three minutes after infusion of 
measurement of hyperaemic blood flow. 
DCE-CT images were reconstructed at a 1.25mm slice thickness, and transferred to 
an image processing workstation (Advantage Windows 4.0; GE Healthcare, Waukesha, 
Wis). Using CT Perfusion 5 program (GE Healthcare, Waukesha, Wis), an arterial input 
curve of contrast medium concentration was generated with a region of interest (ROI) 
placed in the left ventricle chamber of a slice which showed maximum size of the chamber. 
Following which, another ROI was outlined around the contour of the heart in the first 
image of the dynamic series of the same slice. Subsequent images which did not conform 
to this heart outline were removed from the study as they were mis-registered with the first 
image from either breathing or cardiac motion of the animal. Blood flow maps of the 
chosen slice was generated with CT Perfusion 5 software (GE Healthcare, Waukesha, Wis). 
Myocardial blood flow was calculated as the mean pixel value in a ROI placed in the 
inferior wall of the left ventricle. This process was repeated for images acquired following 
dipyridamole injection, and coronary reserve was calculated as the ratio of DIP to basal 
coronary flow.  
 
3.2.4 Positron Emission Tomography 
 
Guinea pigs were anaesthetized in an air tight box with 4-5% isoflurane at 2L/min, 
and injected with ~25kBq/kg (0.2-0.3mL) of [18F] - fluoro-deoxy-glucose ([18F] FDG) via 
the pedal vein. Animals were allowed to recover for 40 minutes in their cage behind a lead 
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brick shield. Animals were then anaesthetized again transferred onto micro-PET scanner 
(GE eXpore Vista DR, GE Healthcare, Waukesha, Wis), and maintained at the 
anaesthetized state with 2.5-3% isoflurane at 1L/min in a nose cone. Images of the heart 
region were acquired by a 20 minute emission. Following correction for scatter and random 
coincidences, images were reconstructed into sixty 0.78mm thick slices. The reconstructed 
images were analyzed using an in-house MATLAB program (MathWorkds Inc., MA, 
USA). Two ROIs were drawn in each slice in which the left ventricle was visible. One 
outlining the epicardial surface, and the other one the endocardial surface of the left 
ventricle. The difference in the total counts was divided by the difference in volume of the 
ROIs to arrive at the average count in the myocardium. This average was converted to 
activity (Bq) using a sensitivity calibration factor determined from routine quality 
assurance of the scanner. The image derived activities from all left ventricle slices were 
averaged together to calculate myocardial activity. Measurements of Standardized Uptake 
Value (SUV) was calculated as: 
 
𝑆𝑈𝑉 =
𝑀𝑦𝑜𝑐𝑎𝑟𝑑𝑖𝑎𝑙 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦
𝐼𝑛𝑗𝑒𝑐𝑡𝑒𝑑 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝐵𝑜𝑑𝑦 𝑊𝑒𝑖𝑔ℎ𝑡⁄
                                                              (1) 
 
 
 
3.2.5 Tissue Collection  
 
 
At approximately postnatal day 250, animals were fasted overnight, and sacrificed 
by CO2 inhalation
23. The heart was removed, trimmed of connective tissue, carefully 
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separated into left or right ventricle, weighed and snaps frozen in liquid nitrogen for RNA 
and protein analysis.  
 
3.2.6 Quantitative Real-Time PCR 
 
Frozen tissues were homogenized in Trizol® (Invitrogen Life Technologies Co., 
Burlington, ON) with mortar and pestle, and 200 µL of chloroform was added. The 
mixtures were centrifuged at 12,000g for 15 minutes at 4°C, and the separated aqueous 
phase was transferred to new RNAse-free tube, and mixed with 500 µL of isopropyl 
alcohol. RNA precipitate were obtained by an additional centrifugation at 12,000g for 10 
minutes at 4°C, and three washes with 75% ethanol at 7500g for 5 minutes. The resulting 
RNA pellet was reconstituted in RNAase free diethylpyrocarbonate water, and yield 
quantity and quality (A260/A280 ration) of RNA was determined with NanoDrop 2000 
UV-Vis Spectrophotometer (Thermo Scientific, Waltham MA, US). To obtain 
complementary DNA, 4µg of RNA were reverse transcribed with Moloney Murine 
Leukemia Virus Reverse Transcriptase (Invitrogen Life Technologies Co., Burlington 
ON). Measurement of gene expressions were completed by Real-time Quantitative 
Polymerase Chain Reaction (qPCR) in a triplicate manner using a Bio-Rad CFX384 real 
time PCR detector (Bio-Rad Laboratories Mississauga, ON). QPCR reactions were 
performed with a denature temperature of 95°C, annealing temperature of 59.5°C and 
elongation temperature of 72°C for 39 cycles. The 2-ΔCT method was used for analysis, with 
β-Actin as the housekeeping gene 24. Primer and genes used are shown in Appendix A.  
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3.2.7 Western Blot 
 
Flash frozen left ventricle tissues were individually pulverized and homogenized in 
RIPA lysis buffer (50 mM Tris-HCl, NP-40 1%, Na-deoxycholate 0.25%, 1mM EDTA, 
150 mM NaCl,  50 mM NAF, 1mM NaV, 25 mM β-glycerophosphate, pH 7.4) with 
protease and phosphatase inhibitor. Homogenates were centrifuged at 10,000g for 15 
minutes at 4°C. The resulting supernatant were isolated as protein preparations, and 
quantified with DC™ Protein Assay Kit (Bio-Rad Laboratories, Mississauga, ON). Using 
6% Bis-Tris gels, 30 µg of protein were separated by size, and then transferred on to 
nitrocellulose membranes. Each membrane was stained with Amido Black stain, and 
imaged with VersaDoc Imaging System (Bio-Rad Laboratories Mississauga, ON) as 
house-keeping. The membranes were then washed and blocked overnight with 5% bovine 
serum albumin at 4°C. Blots were then probed with AKT-1 (Cell Signaling® #4691, 
1:1000), pAKT Serine 473 (Cell Signaling® #9271, 1:1000), pAKT Threonine 308 (Cell 
Signaling® #9275, 1:1000), and monoclonal horseradish peroxidase-conjugated β-actin 
(Sigma-Aldrich #A3854, 1:50000) diluted in 5% bovine serum albumin in Tris-buffered 
saline – Tween 20 (0.01%) for 1 hour at room temperature. After washing, a horseradish 
peroxidase conjugated goat anti-rabbit IgG (Cell Signaling® #7074, 1:1000) secondary 
antibody diluted in 5% bovine serum albumin in Tris-buffered saline – Tween 20 (0.01%) 
was used to incubate blots at room temperature for 1 hour.  Immunoreactive bands were 
detected using Luminata Forte Western HRP Substrate chemi-luminescence (EMD 
Millipore, Darmstadt, Germany), and imaged with VersaDoc Imaging System (Bio-Rad 
Laboratories Mississauga, ON). Abundance of protein were calculated using densitometry 
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values (arbitrary units) determined with ImageLab software (Bio-Rad Laboratories, 
Mississauga, ON), and expressed relative to Amido Black Staining. 
 
3.2.8 Statistical Analysis 
 
Statistical Analysis was performed with SPSS software (SPSS v22.0, Chicago, IL, 
USA). A mixed model ANOVA analysis was used to determine significant differences 
(p<0.05) from age, maternal diet, and postnatal diet. If significant differences or 
interactions were determined, student t-tests were used to for post-hoc analysis of 
differences between groups. 
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3.3 Results 
 
3.3.1 Maternal WD Did Not Result in LBW, or Rapid Catch-Up Growth 
 
We aimed to determine if the consequences of dietary insult, through all life 
exposure, and during pregnancy is translated to the next generation. Offspring from WD 
fed mothers did not demonstrate any reductions in birth weight, or weight/length ratio 
compared to those born from CD fed mothers (Figure 3.1.). Furthermore, offspring growth, 
caloric intake, and food efficiencies from weaning to postnatal day 50, and postnatal day 
50 to 110 were not significantly different between the four groups (Figure 3.2). As a result, 
no initial signs of growth restriction, or the rapid postnatal catch-up growth was observed 
from maternal WD pregnancies when placed on a postnatal CD or WD.  
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Figure 3.1 Birth Characteristics A) Birth weight and B) Weight/length of guinea pig 
pups. Pups were from either CD or WD fed mother bred with a chow fed control male. No 
significant changes in birth weight or weight/length ratio were observed due to maternal 
diet. N= 11 for offspring from CD mothers, and N=12 for offspring from WD fed mothers. 
Box represents Mean and SEM, while whiskers represents Max and Min values. Statistical 
significance was determined by student’s t-test. 
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Figure 3.2 Post-Weaning Growth Characteristics. A) Growth rate, grams gained per 
day. B) Calories consumed per day. C) Food efficiency, gram gained per day/calories 
consumed per day from weaning to postnatal 50 days, and postnatal 50 days to 110 days 
was determined. All data sets are presented by mean ± standard error, and no significant 
changes were observed between all four treatment groups. N=8 (MC/CD), 3 (MC/WD), 6 
(MW/CD), and 4 (MW/WD). Statistical significance was determined by two-way 
ANOVA. 
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3.3.2 Basal and Reserve Coronary Blood Flow Not Affected by Maternal or 
Postnatal WD Consumption 
 
Alterations in basal coronary blood flow have been reported to precede heart failure 
and increases in severity with the onset of cardiomyopathy19,20,25,26.Therefore, in this study, 
baseline coronary blood flow levels were assessed at postnatal 110 days, and 210 days by 
DCE-CT as a marker for CVD development. Coronary blood flow in the inferior wall of 
the left ventricle were compared between maternal diet, postnatal diet, and age factors. 
However, basal coronary blood flow appeared to be consistent across all treatment groups 
(Figure 3.3).  
Reductions in coronary reserve are also strong indicators of cardiomyopathy, and 
systolic dysfunction, particularly in situations of low peripheral arterial resistance where 
basal coronary flow could appear normal17,25,27. However, despite a dipyridamole 
challenge, an average 69% coronary flow increase was observed across all four treatment 
groups (Figure 3.4). Thus, it appears that maternal diet, and postnatal diet do not result in 
changes in coronary reserve as determined by non-invasive imaging at the ages examined. 
Additionally, this study also investigated the mRNA expression of genes which may 
provide insight into possible fibrotic processes in the left ventricle. These included 
Collagen 1, 3, and matrix metalloproteinase-2 (MMP-2). Interestingly, the expression of 
these genes were also not altered as a result of diets in maternal or postnatal period. 
Collectively, these findings suggests that at the ages studied, both maternal and postnatal 
WD consumption did not result in disruptions in coronary circulation and indicators of 
pathological hypertrophy. 
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Figure 3.3 Basal Coronary Blood Flow at 110 and 210 Days. Basal blood flow in the 
inferior wall of left ventricle at A) 110 and B) 210 days of age were determined by CT 
Perfusion 5. No statistical differences were determined between groups. At 110 days N=11 
(MC/CD), 3 (MC/WD), 9 (MW/CD), and 4 (MW/WD). At 210 days N=7 (MC/CD), 1 
(MC/WD), 6 (MW/CD), and 2 (MW/WD). Statistical analyses were performed using a 
two-way ANOVA.   
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Figure 3.4 Coronary Reserve. Mean coronary blood flow was determined prior to after 
dipyridamole stress at 110 days scan. Coronary reserve was calculated as ratio of stress to 
basal coronary flow. No significant differences were observed between the treatment 
groups. N= 7 (MC/CD), 8 (MW/CD), and 3 (MW/WD). Statistical analyses were 
performed using a two-way ANOVA.   
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3.3.3 Postnatal WD Consumption Resulting in Reduced Glucose Uptake 
 
To assess cardiac glucose uptake, as a proxy indicator for insulin sensitivity, PET 
was utilized. Previous studies have reported that during the developmental phase of CVDs, 
IR also develops, and is believed to be a protective mechanism against further cardiac 
injury28–30. Although an interaction between maternal diet and post-natal diet was observed, 
this was not statistically significant (Figure 3.5, p=0.056). However, this trend suggested 
that maternal diet’s effects were not consistent between the different postnatal diets. 
Specifically, a MC/WD mismatch resulted in a 30% decrease in glucose uptake compared 
to MC/CD group.  
Underlying the changes in cardiac glucose uptake is insulin sensitivity. The insulin 
signaling pathway is primarily responsible for the insulin mediate uptake of glucose 
through glucose transporters in the heart, and is primarily regulated by series of 
phosphorylation steps31–33. Specifically, we investigated the protein expression of Protein 
Kinase B (AKT) Threonine 308, Serine 473, and Insulin Receptor Substrate 1 (IRS-1). The 
expression of AKT-1 T308 demonstrated a significant decrease as a result of postnatal 
feeding in both MC and MW groups (Figure 3.6).  Associated markers of insulin signaling, 
IRS-1 and Ser473 AKT-1 were however, unaltered (Figure 3.7).  
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Figure 3.5 Glucose Uptake Determined by PET. Standard Uptake Value of the left 
ventricle acquired by PET at A) 110 and B) 210 days. Data presented as Mean ± Standard 
Error. No statistical significance was observed between groups at both time point. At 110 
days N= 11 (MC/CD), 3 (MC/WD), 6 (MW/CD), and 5 (MW/WD). At 210 days N= 8 
(MC/CD), 3 (MC/WD), and 3 (MW/WD). Box represents Mean and SEM, while whiskers 
represents Max and Min values. Statistical significance was determined by a repeated 
measures two-way ANOVA. ANOVA table presented in Appendix I 
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Figure 3.6 Protein Expression of pAKT (T308) at Putdown.  Expression of pAKT 
(T308) relative to total AKT-1 protein in the left ventricle at 240 days of age. *p<0.05. 
N=11 for CD, and N=9 for WD groups. Statistical significance was first determined by 
two-way ANOVA, and further analyzed by student’s t-test. Box represents Mean and SEM, 
while whiskers represents Max and Min values. ANOVA table presented in Appendix J 
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Figure 3.7 Protein Expression of pIRS (S307) and pAKT (S473) at Putdown. Protein 
expression of A) Serine 307 pIRS relative to total IRS protein, and B) Serine 473 pAKT 
relative to total AKT-1 protein expression No significant differences were observed. N=7 
(MC/CD), 4 (MC/WD), 4 (MW/CD), and 5 (MW/WD). Statistical significance was 
examined by two-way ANOVA 
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3.4 Discussion 
 
This current study explored the consequences of WD, particularly its influences in 
utero, and in postnatal life on the development of CVDs in offspring as they mature into 
adulthood. Interestingly, maternal WD consumption from weaning through maturation and 
pregnancy did not appear to aggravate cardiac function in the next generation, which are 
either control fed or further challenged with a postnatal WD. We believe that due to in 
utero adaptation to maternal diets, maternal WD may not have prominent or direct effects 
on offspring health at the age studied. Quite possibly, maternal obesity, or further postnatal 
diet challenge is necessary to fully elucidate the programming effects of a maternal WD34. 
However, we can speculate from related studies that given maternal WD’s effects on other 
organ systems, and its long term predisposition for further postnatal insult, it can impact 
cardiovascular function later in adulthood.  
In contrast to the Uterine Artery Ablation (UAA) model used in the previous 
chapter, a maternal WD introduces an abundance of carbohydrates, and saturated fatty 
acids. We have already determined that restriction in fetal nutrients is associated with 
LBW, and by late adulthood, left ventricular hypertrophy like symptoms. Other studies 
have also determined that LBW (induced by maternal hypoxia) and other extreme prenatal 
insults such as maternal obesity, resulting in large birth weight, and poor postnatal 
outcomes when challenged with an adverse postnatal high fat diet insult9,35,36. Consumption 
of WD in postnatal life is known to result in the development of chronic diseases such as 
CVD, even in individuals born of NBW37,38. Naturally, we are interested in whether 
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prolonged exposure to WD, particularly during in utero period, can accelerate or 
exacerbate these processes.  
We observed that lifelong maternal WD feeding did not yield LBW pups. Studies 
in non-human primates reported that maternal consumption of a high fat diets increases the 
risks of placental inflammation, and stillbirth, and more importantly, it was also associated 
with a reduction in uterine artery blood flow39. This revelation is analogous to the UAA 
model, and we predicted that a lifelong a maternal WD would result in similar 
consequences, however that was not the case. Although high energy diet consumption and 
obesity during pregnancy are associated with IUGR40, fetal overgrowth and large-for-
gestational age is not uncommon41,42. In support, studies have suggested that prenatal 
programming of IR, and birthweight alterations may be more associated with maternal 
adiposity than dietary fat34.  However, in this study, despite chronic WD feeding in 
mothers, they were by no means overweight, which perhaps provides an explanation for 
the lack of the extreme birth weight phenotypes in the offspring. Furthermore, offspring of 
postnatal growth and food efficiencies were similar across the treatment groups, therefore 
a postnatal catch-up growth profile commonly associated with development of chronic 
diseases was not apparent. However, adverse prenatal environment can still possibly give 
rise to adult chronic diseases, such as obesity, IR, and cardiac dysfunction later in 
adulthood9,35,39,43,44. As a result, we are interested in the effects of postnatal WD 
consumption, and how they might play a role in the development of chronic diseases in the 
offspring, particularly in combination with chronic maternal WD insult.  
In the build-up to many CVDs such as cardiomyopathy, disturbances in coronary 
circulation can occur, providing a useful predictor of cardiac dysfunction45,46. Utilizing 
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DCE-CT, baseline coronary flow in the left ventricle microvasculature at postnatal day 110 
and 210 were measured. Interestingly, no alterations in coronary blood flow was observed 
between the groups. However, baseline coronary flow may not be a definitive indicator of 
coronary complications. This is particularly important, as basal coronary blood flow can 
still be maintained at normal levels by reducing distal arterial resistance, therefore masking 
the disturbances in coronary physiology27. However, when challenged, the ratio of stressed 
to basal blood flow, or the coronary reserve of compromised hearts is diminished27. 
Inducing stress through dipyridamole creates a discrepancy between the blood flow of 
stenosed and normal coronary arteries, which can provide further insight on the changes of 
left ventricular hemodynamics. Intriguingly, despite a dipyridamole challenge, coronary 
reserve was similar across all four treatment groups. This observation was akin with our 
previous findings, where postnatal WD feeding alone was not associated with coronary 
disruptions and markers of left ventricular hypertrophy. This study draws an additional 
revelation in that offspring of maternal WD feeding also did not display hemodynamic 
alterations in the left ventricle. 
Maternal high-fat feeding have been strongly associated with the development 
metabolic diseases development in later life, with cardiac IR as a strong indicator9,22,47. 
Furthermore, in conjunction with a post-natal WD challenge, development of hypertension, 
and heart failure can be further exacerbated48. A previous study have reported 
cardiomyocyte glucose intolerance resulting from high-fat diet feeding23 Therefore, early 
diagnosis of pre-clinical markers such as cardiac IR is important. The PET technology 
opens up the possibility of detecting changes in glucose uptake in the left ventricle and 
identifying at risk individuals in a non-invasively manner. In this chapter, no statistical 
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differences in left ventricular glucose uptake was found, yet a strong interaction between 
maternal diet and postnatal diet may be at play. Where, offspring of a CD fed mother 
displayed lower glucose uptake when given a postnatal WD compared to offspring born of 
WD fed mothers that were also fed the same postnatal WD. In comparison, this pattern was 
reversed with postnatal CD, where maternal CD offspring displayed higher glucose uptake 
compared to offspring from a WD fed mother. Furthermore, molecular analyses revealed 
that a postnatal WD alone was associated with a reduced protein expression of 
phosphorylated T308. Typically, the phosphorylation of T308 is an important step in the 
insulin signaling pathway, which ultimately translates to the translocation of glucose 
transporters to the membrane49. This is yet another piece of evidence which suggests that 
at adulthood, these offspring displayed reduced glucose uptake and associated IR in the 
heart as a result of WD consumption in postnatal life. This is also in alignment with our 
results in the LBW model, where changes in cardiac insulin sensitivity are largely 
determined by postnatal diet.  
These changes in cardiac glucose uptake also highlights in utero programming at 
work, where the prenatal environment is largely influential on the offspring’s adaptability 
to the postnatal environment. Specifically the mismatch between maternal and postnatal 
diet introduces susceptibilities in cardiac glucose uptake. The fetus is programmed to adapt 
its growth and developmental profiles during adverse uterine environments to ensure its 
survival in a similar postnatal environment. This hypothesis harkens back to the studies on 
Dutch hunger winter, and the Leningrad Siege, which clearly demonstrates how glucose 
tolerance and other metabolic diseases are associated with a mismatch of prenatal and 
postnatal environments50–52. In support, a study has reported that in response to maternal 
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high fat diet, offspring development of endothelial dysfunction in adulthood was prevented 
if offspring were raised on the same diet53. This however, is not to say that offspring born 
of a WD pregnancy should continue to indulge on the unhealthy diets, as ultimately it did 
not prevent the development of hypertension, and may pose a higher risk in the long term53. 
Additionally, this inferred that postnatal dietary factors might play a more influential role 
in the outcome of cardiac insulin sensitivity at the young adult age. It is possible that 
maternal dietary effects may not yet be discernable at the young ages studied. A non-human 
primate study reported that offspring of chronic maternal high-fat diet animals that 
underwent a diet reversal just prior to breeding retained normal acetylation of histone H3, 
where its alteration is commonly accompanied by nonalcoholic fatty liver diseases54. 
Maternal WD effects may not be prominent at first, and may require an additional insult, 
such as a postnatal WD, to be fully elucidated. Although studies on maternal diet reversal 
and CVD developments are lacking, we can speculate that the associated effects of a 
maternal WD requires long term exposure, and predisposes the offspring to further insult 
from a postnatal WD challenge5,10. 
Although chronic maternal WD consumption did not yield the same hallmarks of 
hypertrophic cardiomyopathy observed in the LBW model. Previous studies have reported 
the susceptibility of a pregnancy marred by a high-fat diet to the development of chronic 
diseases such as CVDs. For example, offspring of chronic maternal high-fat feeding in rats 
displays increased body weight, and insulin insensitivity by adulthood6. Additionally, these 
changes appears to be highly heritable, where it has been observed to persist onwards to 
the second generation, and are believed to be a result of changes in epigenetics55. At the 
cardiovascular level, offspring of high-fat fed moms are also associated with endothelial 
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dysfunction, and are moderately exacerbated by a postnatal high-fat diet consumption56. 
Interestingly, endothelial function appears to improve when offspring are switched to a 
control diet, further supporting the notion that postnatal dietary patterns may be more 
detrimental to cardiac health56. Comparatively, in this current study, alterations in coronary 
circulation were not observed even in adulthood. A possible explanation is that the onset 
of CVDs may not occur until later in adulthood. In support, epidemiological studies in 
humans highlighted the increased prevalence of CVD development and fatalities in men 
were associated with high saturated fatty acid consumption. However, the onset of these 
fatal CVDs tend to be in middle age at approximately ~55 years old, where early age 
development is categorized as <70 years of age57–60. Therefore we must consider the 
possibility that the onset of these complications in the guinea pigs may be well into middle 
to late adulthood.  
Although poor maternal diet may not appear to play a direct role on CVD 
development in offspring at the age studied, we speculate that the offspring’s predisposition 
for further insult from postnatal diets is a major risk factor in long term cardiac health. 
Previous studies with chronic maternal high-fat feeding have demonstrated severe 
consequences in other organ systems by adulthood in the offspring. For instance, maternal 
high-fat diet exposure has been linked to development of non-alcoholic liver disease, beta 
cell dysfunction and obesity in offspring6,55,61,62. Although maternal WD consumption may 
not be a primary influence on later life cardiovascular outcome, the onset of obesity, 
diabetes and diseases of other organ systems may impact cardiac function overall, leading 
to the emergence of CVDs later in adulthood63,64. Furthermore, chronic exposure to WD in 
postnatal life is also associated with the development of similar complications such as IR 
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and obesity. We speculate that when combined with the aforementioned maternal WD 
effects, severe cardiovascular complications may arise with age. Therefore, the long term 
implications of a maternal WD on CVD development should be further investigated in 
future studies.  
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4 Discussion 
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4.1 Summary 
 
Since Forsdahl and Barker put forth the idea of Developmental Origins of Health 
and Disease, many have started to recognize the importance of in utero environments on 
the onset of adult diseases. This hypothesis, now further expanded, suggests that the 
development of chronic metabolic diseases in later life are the result of fetal programming 
mechanisms during critical periods of in utero environment1–3. In particular, a suboptimal 
in utero environment, resulting in Low Birth Weight (LBW), and an altered postnatal 
growth profile is strongly believed to increase the risk of developing chronic diseases such 
as Cardiovascular Diseases (CVDs) in later life1,4. These adverse in utero environments, 
can be a result of placental insufficiencies (PI), where the inability to provide the required 
oxygen and nutrient supply to the fetus induces a state of growth restriction. In contrast to 
a restrictive insult, adverse in utero environments can also arise from excessive maternal 
consumption of unhealthy diets such as a Western Diet (WD) through life and pregnancy. 
Alarmingly, recent evidence have also suggested that postnatal insults such as the 
consumption of WD can further exacerbate the abnormal growth patterns resulting from in 
utero insults5. Given the increasing prevalence of WD, its exposure to individuals of an 
adverse in utero environment may enhance the detrimental consequences of the growth 
restricted developmental profile. However, the mechanisms and relationships in the 
combination of prenatal and postnatal factors on the development of chronic diseases are 
still unknown.  
Of the many non-communicable diseases associated with fetal programming, CVD 
distinguishes itself with the highest mortality rate. In 2008, approximately 17.3 million 
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people worldwide died from complications related to CVDs, and this number is expected 
to rise in the future6,7.  Prior to the onset of severe functional phenotypes of CVDs, disease 
progression in the myocardium is often marked by cardiac IR, and pre-clinical markers 
such as hypertrophy, as well as alterations in coronary circulation8–12. It is likely that the 
development of CVDs may stem from the in utero period, and further hampered by 
unhealthy diet consumption. Given the severity of the consequences, such as systolic 
dysfunction, heart failure, and ultimately death, it is therefore crucial to investigate possible 
diagnostic techniques which could detect these early pre-clinical markers of CVDs.  
 In Chapter 2, we investigated the associated effects of low birth weight (LBW) 
resulting from a restrictive in utero environment and postnatal exposure to WD on the 
potential for CVD development in adulthood. We postulated that LBW, and WD 
consumption combined would result in the development of early pre-clinical markers of 
CVDs. Our findings demonstrated that LBW offspring displayed a rapid catch up growth 
profile shortly after birth. This accelerated growth trajectory has been implicated as an 
underlying factor in the manifestation of chronic diseases such as CVD13–15. Indeed, using 
Dynamic Contrast Enhanced Computed Tomography (DCE-CT), this study also 
highlighted that this accelerated growth in LBW animals was associated with a reduction 
in basal coronary blood flow at postnatal day 110. Moreover accompanying these 
alterations in coronary flow was histological evidence of pathological hypertrophy, 
including cardiomyocyte enlargement, and fibrosis. However these changes were not 
associated with the postnatal consumption of WD. In comparison, WD consumption was 
associated with reductions in left ventricular glucose uptake, as indicated by Positron 
Emission Tomography (PET). This was also supported by a decreased protein activation 
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of AKT-1, therefore possibly contributing to a state of cardiac IR. While in utero 
environment and WD consumption independently displayed different components of 
compromised cardiac health, their combination however, did not appeared to result in an 
exacerbated effect at the ages studied. 
In Chapter 3, we expanded our experimental focus on chronic maternal WD 
consumption as means of prenatal insult. Maternal WD consumption have been reported 
to trigger placental inflammation, and disruptions in placental hemodynamics, which is 
also associated with a higher frequency of stillbirths, and prenatal complications16,17. 
Furthermore, this unhealthy maternal dietary pattern is associated with the development of 
cardiovascular complications such as endothelial dysfunction, hypertension, and IR in the 
offspring18–20. Of additional concern is the possibility that the vulnerability induced by an 
in utero exposure to WD can be aggravated by a postnatal consumption of the same 
unhealthy WD18. However, detailed studies investigating their combined effects on CVDs 
are still lacking. In this chapter, we demonstrated that basal coronary flow and coronary 
reserve following a dipyridamole challenge were not significantly altered from either 
maternal or postnatal WD feeding. PET studies however indicated a strong trend which 
suggested that maternal WD may have differential effects on offspring cardiac glucose 
uptake depending on the type of postnatal diet consumed. Specifically, this highlights the 
effects of a mismatched in utero and postnatal environment, where reductions in cardiac 
glucose uptake appears to be more severe in maternal control diet to WD group than 
maternal WD to WD group. Although maternal WD’s effects on cardiac health may not 
yet be discernable at the ages studied, this study further supported our observation in 
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Chapter 2, where postnatal WD consumption is linked to cardiac glucose uptake 
reductions, which are suggestive of IR.  
In summary, these studies provide evidence for in utero programming of CVDs in 
adulthood. In particular, the growth restriction and LBW insult appear to have significant 
consequences in the early development of pathological hypertrophy. Moreover, both 
studies demonstrated the impact of postnatal WD consumption on the onset of markers of 
CVDs in early adulthood. Offspring of chronic maternal WD treatment appears to be free 
of the pre-clinical markers of CVDs at the ages studied. However, it is certainly possible 
that with age, a postnatal insult can unmask these in utero programmed risks as observed 
in reports of HFD, and IUGR interactive studies21. Lastly, although offspring appear 
healthy and non-obese while maintaining whole body glucose tolerance (K. Dunlop, per 
comms), important preclinical markers of CVDs such as disruptions in coronary flow and 
cardiac glucose uptake are present. A key significance of this study, is the applicability of 
imaging modalities, which effectively and non-invasively highlight these key 
developmental markers of CVD prior to the onset of a disease phenotype. 
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4.2 Speculations 
 
Adverse in utero environments are known risks for the development of heart diseases, such 
as cardiomyopathy in later life4,22. This disease of the myocardium may have its origins in 
utero due to the unfavourable conditions during cardiovascular development. For example, 
a common cause of growth restriction and LBW is placental insufficiency, where the 
placenta fails to provide the required oxygen and nutritional needs of the fetus23. PI can 
also induce an increase in placental vascular bed resistance, as a result, fetal hearts must 
overcome this increased mechanical force for ejection, thereby creating pressure 
overload24,25. This complication predisposes the offspring to the development of 
hypertrophy, as concentric hypertrophy is induced by chronic increases in ventricular 
pressure26,27. Since this onset of pressure overload occurs in such an early stage during fetal 
development, it explains the early presence of left ventricular hypertrophy in LBW 
offspring. Moreover, in utero complications during fetal cardiac development can also 
hinder cardiac growth, resulting in a reduction in cardiomyocyte number at birth22. 
However, the heart is a post-mitotic organ, therefore postnatal growth is dependent on 
hypertrophy, or proliferation of non-myocytes22,28. This is further exacerbated by a 
postnatal catch-up growth profile that puts additional pressure for rapid cardiac growth. 
When the postnatal heart reaches its capacity for hypertrophic growth, further growth will 
occur through the deposition of extracellular matrix, therefore beginning the process of 
cardiac fibrosis29. This onset of pathological hypertrophy, characterized by fibrosis, can 
then lead to severe functional consequences such as cardiac dysfunction30. In our study the 
development of hypertrophy and fibrosis were also accompanied by reductions in basal 
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coronary flow. Interestingly, since hypoxia during in utero restriction is a stimulus for 
coronary vascularization, why is it that our study observed the opposite31? Other studies 
have supported our observation, where maternal restriction was not associated with any 
increases in coronary vascularization29. Perhaps this can be explained by an associated 
effect of hypertrophy and fibrosis, which is the reduction in coronary capillary density32. 
These mechanisms are likely what underlie the presence of pathological hypertrophy and 
reductions in coronary blood flow in the LBW offspring. However, these were not present 
in offspring from the chronic maternal WD model. Although a maternal WD insult may 
share similarities with a growth restriction insult, it can result in different outcomes 
including LBW and large birthweight18,33,34. Furthermore, its effects on postnatal health 
can easily be reversed35. This led us to believe that maternal WD’s effects on offspring 
CVD development may be indirect. This is further supported by the fact that maternal WD 
offspring did not demonstrate signs of LBW, or the rapid catch-up growth profile that is 
usually associated with chronic diseases development in later life. 
Similarly, the development of cardiac IR is another pre-clinical marker of many 
CVDs11,12. This state of IR, accompanied by a greater demand on fatty acid oxidation as a 
fuel source during high-fat feeding can be seen as a protective mechanism against cardiac 
dysfunction36. This state of IR can be attributed to the high levels of saturated fatty acids 
present in the WD. For example, high levels of saturated fatty acids have been known to 
increase the secretion of inflammatory cytokines which impair insulin sensitivity in skeletal 
muscle cells37,38. More importantly, saturated fatty acids can also reduce the activity of 
peroxisome proliferator-activated receptor gamma coactivator 1- alpha (PGC-1α), 
resulting in a reduction in oxidative phosphorylation and insulin-stimulated glucose 
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uptake39. Eventually, the onset of severe CVDs occurs when fatty acid oxidation is 
maladapted40–42. For example, studies have reported that the expression of peroxisome 
proliferator-activated receptor alpha  (PPAR-α) – an important activator of fatty oxidation 
-  is reduced, while glucose metabolism was increased in rats with pathological 
hypertrophy42,43. The accumulation of saturated fatty acids, and its harmful by-products 
such as reactive oxygen species (ROS), diacylglycerols (DAG), and ceramide may result 
in the onset of fibrosis, and cardiac dysfunction44–47.  Our present findings appeared 
consistent with these reports, where a postnatal WD depression in basal glucose uptake 
was observed. Additionally, early indication of fibrosis was also present in WD fed animals 
in chapter 2. This purported that the WD fed guinea pigs, with the reductions in glucose 
uptake, likely indicates an early stage of CVD development, with severe cardiovascular 
related consequences in later life. 
  
134 
 
4.3 Potential Limitations and Future Improvements 
 
Given the ambitious scope, and detail of this study, there are certainly some 
limitations that must be addressed. Firstly, this study only chose to examine the pre-clinical 
parameters with non-invasively imaging at three different time points, 50, 110, and 210 
days. These ages were strategically selected based on a previous study which demonstrate 
that the onset of IR, a key marker of metabolic disease development in guinea pigs occurred 
around 101 days48. However, they could not fully encompass the early developmental 
period in guinea pig adolescence, nor later in adulthood where CVDs typically occur. 
Future studies should introduce additional scanning time points to fully assess the 
progression of CVD development. In particular, future studies should also focus on the 
later life in utero induced multi-organ failure and its relation to CVD development to 
ascertain the developmental implications of in utero insults. Studies should also introduce 
molecular analysis immediately following scanning to further strengthen the findings of 
the non-invasive imaging techniques. 
 Secondly, non-invasive assessment of coronary blood flow using DCE-CT in a 
small animal model have many physical limitations. For example, the rapid heart rate, and 
breathing of guinea pigs introduces motion in the generation of blood flow maps. Although 
our study compensated for motion with the removal images where the heart shape was not 
consistent, this method was not perfect. A solution to this problem is to intubate the animals 
during the scanning procedure. However this would induce further stress to the animal. 
Future imaging studies should investigate techniques which can fully translate the use of 
clinical DCE-CT on small animal research. Despite this, the significance of DCE-CT for 
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the detection of preliminary clinical markers should not be ignored. Many of these 
limitations do not apply to human subjects – the intended subject of these imaging 
modalities– where it has been extensively been used for the study of coronary 
circulation49,50.   
Another limitation in chapter 2 was that coronary flow was determined at a basal 
state, and therefore was not a definitive indicator of coronary complications. Basal 
coronary blood flow can be maintained at normal levels by reducing distal arterial 
resistance, therefore masking the disturbances in coronary physiology51. However, when 
under stress, the coronary reserve - the ratio of increase in coronary flow from stress to 
basal levels - of these compromised hearts are diminished51. Therefore, in future studies, 
coronary reserve of the LBW model must be examined similar to chapter 3. Moreover, we 
have speculated that the onset of hypertrophy and fibrosis underlies the reductions in 
coronary blood flow due to a reduction in capillary density32. Therefore, in addition to 
histological analysis on cardiomyocyte enlargement, and collagen deposition, future 
studies should also investigate ventricular capillary density. This could further strengthen 
and ascertain the relationship between in utero insult and coronary vascularization during 
CVD development. 
 Thirdly, the in vivo assessments of glucose uptake by PET were performed under 
basal conditions, as opposed to an insulin stimulated dynamic assessment. Similarly the 
final tissue collection for molecular analysis were also performed under fasted states in 
basal conditions. Measurement of glucose uptake under insulin stimulated situations could 
further strengthen our claim of changing insulin sensitivity, given this approach would 
demonstrate the implications of the disruptions in the insulin signaling pathway. Therefore 
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future [18F] FDG-PET studies should be conducted following insulin administration to 
determine the cardiovascular response to insulin. Previous studies which utilized a 
hyperinsulinemic clamp prior to [18F] FDG PET clearly demonstrated decreases in cardiac 
and skeletal glucose uptake that were associated with insulin resistance36,52,53. Similarly, 
tissue collection immediately following insulin injection would also allow us to investigate 
the changes in the insulin signaling pathway in response to insulin, and provide further 
support of an insulin resistant state.  
 Lastly, is the limitation in the characterization of a late stage severe CVD. In this 
study, we proposed that the pre-clinical markers such as coronary blood flow reductions, 
cardiac IR, and hypertrophy are precursors to a more severe phenotype of CVD. Indeed 
studies have demonstrated that these parameters have been used to effectively predict the 
onset of severe complications such as cardiac dysfunction, and death8,9,54–58. However, this 
study is limited in that a severe diseased phenotype was not characterized. Future studies 
should investigate an endpoint result from the prenatal and dietary insults, such as the onset 
of severe cardiac dysfunction. We propose the use of more traditional imaging systems 
such as echocardiography, where the measurement of ejection fraction is a useful tool in 
the characterization of deteriorating cardiac function59.  
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4.4 Conclusions 
 
This present study highlights the implications of an in utero insult, and a postnatal 
WD insult on the development of early preliminary clinical markers of CVD. Despite the 
healthy, non-obese, and glucose tolerant phenotype, we believe that the changes in the 
cardiovascular system exposes the underlying development of severe cardiovascular 
complications. Abnormal cardiac development processes may arise from prenatal insults, 
and the rapid catch-up growth profile. These inherent risks manifest themselves, and result 
in the onset of early development of pre-clinical markers of CVD such as hypertrophy, and 
coronary circulation alterations. Furthermore, our categorization of LBW based on the 25th 
percentile also inferred that there are potentially many at risk individuals outside of the 
clinically defined 10th percentile cutoff. This further supports the idea that offspring that 
have undergone a reprogramming event due to sub-optimal in utero conditions may not be 
fully reflected by the clinical birthweight cutoff at 10th percentile60,61. Interestingly, 
maternal WD did not appear to play a direct role in the development of CVDs. However, 
postnatal WD consumption resulted in alterations in cardiac glucose uptake, again 
indicative of eventual CVD development. Studies in our group, and other reports have 
demonstrated that in utero insults such as LBW, or a chronic maternal high-fat diet were 
associated with non-alcoholic liver disease, obesity, and dysfunctions in vascular function, 
and adipose development15,17,62–65. It is possible that these associated secondary effects of 
in utero insults such as LBW, or maternal WD consumption on other organ systems can 
eventually impact cardiac function, and lead to development of CVDs66,67. More 
importantly, chronic postnatal exposure to WD is also associated with similar 
138 
 
complications such as IR, and obesity, and can therefore enhance the deleterious effects of 
in utero insults. We propose that given the shared consequences of in utero and postnatal 
insults, the culmination of these complications would exacerbate and accelerate the 
development of CVDs in adulthood. Lastly this study also demonstrated the significance 
of non-invasive imaging on the early detection of markers of CVD development. The 
ability to identify at risk individuals before the onset of severe complications is important 
for the proposal of more effective treatment therapies. In summary the findings of this 
study not only highlighted the risks of in utero and postnatal insults on CVD development, 
but also opened new doors on the study of early diagnosis and intervention of the diseases 
which increasingly plague our society.  
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Appendix A. Primer sequences of selected target genes utilized in real-time PCR. 
 
Gene Accession Number F R 
αSMA ENSCPOT00000010480 AGCAAGAGAGGTATCCTGAC CGCAGCTCATTGTAGAAAGT 
Collagen 
1 
XM_003466865.1 AACGGAGACACCTGGAAACC TTGACTAGGTCCAGGGCTGA 
Collagen 
3 
XM_003478706.1 TGCTACTTTGAACCGCTTTT TTCATCAACTTCCTGGGTCT 
MMP-2 XM_003477541.1 CAGGGCACCTCCTACAACAG CCTTCTGAGTTCCCACCGAC 
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Appendix B. Ethics Approval 
                      
06.03.2010  
  
     *This is the Original Approval for this protocol*  
*A Full Protocol submission will be required in 06.30.2014*  
  
Your Animal Use Protocol form entitled:  
In Utero Origins of Adult Insulin Resistance  
Funding Agency  CIHR - Grant #R3826A09   
has been approved by the University Council on Animal Care. This approval is valid 
from 06.03.2010 to 06.30.2011.   
The protocol number for this project is 2010-229.   
This number must be indicated when ordering animals for this project.  
Animals for other projects may not be ordered under this number.  
If no number appears please contact this office when grant approval is received.  
     If the application for funding is not successful and you wish to proceed with the 
project, request that an internal scientific peer review be performed by the Animal Use 
Subcommittee office.  
Purchases of animals other than through this system must be cleared through the ACVS 
office.  Health certificates will be required.  
  
ANIMALS APPROVED FOR 4 Years      
Species  Strain  Other Detail  
Pain 
Level  
Animal # Total  
for 4 Years  
Guinea Pig  Hartley  Pregnant ~25 Days on Arrival  C  556  
 
The holder of this Animal Use Protocol is responsible to ensure that all associated safety components 
(biosafety, radiation safety, general laboratory safety) comply with institutional safety standards and have 
received all necessary approvals.  Please consult directly with your institutional safety officers.  
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Appendix C. ANOVA Table for Figure 2.3 Basal Coronary Blood Flow Determined 
by DCE-CT. 
 
Tests of Between-Subjects Effects 
Dependent Variable: Blood Flow 
Source 
Type III Sum 
of Squares df Mean Square F Sig. 
Partial Eta 
Squared 
Corrected Model 85632.376a 15 5708.825 1.064 .403 .166 
Intercept 3200825.235 1 3200825.235 596.304 .000 .882 
Sex 2059.209 1 2059.209 .384 .537 .005 
BirthType 1331.536 1 1331.536 .248 .620 .003 
Diet 3436.354 1 3436.354 .640 .426 .008 
Age 1162.622 1 1162.622 .217 .643 .003 
Sex * BirthType 408.484 1 408.484 .076 .783 .001 
Sex * Diet 2191.975 1 2191.975 .408 .525 .005 
Sex * Age 3066.114 1 3066.114 .571 .452 .007 
BirthType * Diet 16410.451 1 16410.451 3.057 .084 .037 
BirthType * Age 22302.282 1 22302.282 4.155 .045 .049 
Diet * Age 2220.977 1 2220.977 .414 .522 .005 
Sex * BirthType * Diet 4188.972 1 4188.972 .780 .380 .010 
Sex * BirthType * Age 474.092 1 474.092 .088 .767 .001 
Sex * Diet * Age 5259.104 1 5259.104 .980 .325 .012 
BirthType * Diet * Age 11771.423 1 11771.423 2.193 .143 .027 
Sex * BirthType * Diet * 
Age 
1536.422 1 1536.422 .286 .594 .004 
Error 429421.793 80 5367.772    
Total 4043459.083 96     
Corrected Total 515054.169 95     
a. R Squared = .166 (Adjusted R Squared = .010) 
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Appendix D. ANOVA Table for Figure 2.4 Cardiac Glucose Uptake by PET 
 
 
Tests of Between-Subjects Effects 
Dependent Variable: SUV 
Source 
Type III 
Sum of 
Squares df Mean Square F Sig. 
Partial Eta 
Squared 
Corrected Model 17.612a 15 1.174 1.996 .024 .254 
Intercept 353.522 1 353.522 600.876 .000 .872 
Sex .235 1 .235 .399 .529 .005 
BirthType .330 1 .330 .560 .456 .006 
Diet 6.940 1 6.940 11.796 .001 .118 
Age .557 1 .557 .947 .333 .011 
Sex * BirthType .245 1 .245 .416 .520 .005 
Sex * Diet .249 1 .249 .423 .517 .005 
Sex * Age 1.314 1 1.314 2.233 .139 .025 
BirthType * Diet .991 1 .991 1.684 .198 .019 
BirthType * Age .127 1 .127 .215 .644 .002 
Diet * Age 1.607 1 1.607 2.731 .102 .030 
Sex * BirthType * 
Diet 
.878 1 .878 1.493 .225 .017 
Sex * BirthType * 
Age 
.230 1 .230 .391 .533 .004 
Sex * Diet * Age .365 1 .365 .621 .433 .007 
BirthType * Diet * 
Age 
1.966 1 1.966 3.341 .071 .037 
Sex * BirthType * 
Diet * Age 
.930 1 .930 1.581 .212 .018 
Error 51.774 88 .588    
Total 507.525 104     
Corrected Total 69.387 103     
a. R Squared = .254 (Adjusted R Squared = .127) 
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Appendix E. ANOVA Table for Figure 2.5 Cross-Sectional Area of Cardiomyocytes 
 
 
 
Tests of Between-Subjects Effects 
Dependent Variable: Surface Area of Cardiomyocytes 
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Partial Eta 
Squared 
Corrected Model 50224.931a 7 7174.990 3.027 .026 .527 
Intercept 2051230.300 1 2051230.300 865.426 .000 .979 
Sex 4532.849 1 4532.849 1.912 .183 .091 
BW 15683.581 1 15683.581 6.617 .019 .258 
Diet 919.696 1 919.696 .388 .541 .020 
Sex * BW 7925.713 1 7925.713 3.344 .083 .150 
Sex * Diet 7416.964 1 7416.964 3.129 .093 .141 
BW * Diet 1486.110 1 1486.110 .627 .438 .032 
Sex * BW * Diet 3533.122 1 3533.122 1.491 .237 .073 
Error 45033.740 19 2370.197    
Total 2661565.249 27     
Corrected Total 95258.671 26     
a. R Squared = .527 (Adjusted R Squared = .353) 
 
  
152 
 
Appendix F. ANOVA Table for Figure 2.6 Collagen Content in the Left Ventricle 
 
 
 
Tests of Between-Subjects Effects 
Dependent Variable: Fibrosis, Collagen percentage 
Source 
Type III Sum 
of Squares df Mean Square F Sig. 
Partial Eta 
Squared 
Corrected Model 34.094a 7 4.871 3.232 .021 .557 
Intercept 141.860 1 141.860 94.126 .000 .839 
Sex 1.695 1 1.695 1.124 .303 .059 
BW 11.946 1 11.946 7.927 .011 .306 
Diet .848 1 .848 .563 .463 .030 
Sex * BW .020 1 .020 .014 .909 .001 
Sex * Diet 7.469 1 7.469 4.956 .039 .216 
BW * Diet 7.542 1 7.542 5.004 .038 .218 
Sex * BW * Diet 19.298 1 19.298 12.805 .002 .416 
Error 27.128 18 1.507    
Total 202.192 26     
Corrected Total 61.222 25     
a. R Squared = .557 (Adjusted R Squared = .385) 
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Appendix G. ANOVA Table for Figure 2.7 Type 1 Collagen mRNA Expression 
 
 
Tests of Between-Subjects Effects 
Dependent Variable: Collagen Type 1 mRNA 
Source 
Type III Sum 
of Squares df Mean Square F Sig. 
Partial Eta 
Squared 
Corrected Model .128a 7 .018 3.020 .022 .490 
Intercept .681 1 .681 112.110 .000 .836 
Sex .069 1 .069 11.408 .003 .341 
BW .018 1 .018 3.041 .095 .121 
Diet .023 1 .023 3.774 .065 .146 
Sex * BW .031 1 .031 5.147 .033 .190 
Sex * Diet .001 1 .001 .178 .677 .008 
BW * Diet .005 1 .005 .784 .386 .034 
Sex * BW * Diet 3.715E-5 1 3.715E-5 .006 .938 .000 
Error .134 22 .006    
Total .934 30     
Corrected Total .262 29     
a. R Squared = .490 (Adjusted R Squared = .328) 
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Appendix H. ANOVA Table for Figure 2.8 AKT Expression in the Left Ventricle at 
Putdown. 
 
 
Tests of Between-Subjects Effects 
Dependent Variable: Ratio of pAKT (T308) 
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Partial Eta 
Squared 
Corrected Model .009a 7 .001 2.580 .032 .368 
Intercept .195 1 .195 408.745 .000 .930 
Sex .003 1 .003 6.875 .013 .182 
BW .001 1 .001 2.745 .108 .081 
Diet .002 1 .002 5.060 .032 .140 
Sex * BW .000 1 .000 .303 .586 .010 
Sex * Diet .000 1 .000 .452 .506 .014 
BW * Diet .001 1 .001 1.784 .191 .054 
Sex * BW * Diet .001 1 .001 1.757 .195 .054 
Error .015 31 .000    
Total .216 39     
Corrected Total .023 38     
a. R Squared = .368 (Adjusted R Squared = .225) 
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Appendix I. ANOVA Table for Figure 3.5 A. Glucose Uptake Determined by PET 
 
 
 
Tests of Between-Subjects Effects 
Dependent Variable: SUV 
Source 
Type III Sum 
of Squares df Mean Square F Sig. 
Partial Eta 
Squared 
Corrected Model 2.581a 3 .860 1.654 .207 .191 
Intercept 66.294 1 66.294 127.425 .000 .859 
Pregnancy .782 1 .782 1.503 .234 .067 
Diet .532 1 .532 1.022 .324 .046 
Pregnancy * Diet 2.129 1 2.129 4.092 .056 .163 
Error 10.925 21 .520    
Total 107.195 25     
Corrected Total 13.507 24     
a. R Squared = .191 (Adjusted R Squared = .076) 
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Appendix J. ANOVA Table for Figure 3.6 Protein Expression of pAKT (T308) at 
Putdown. 
 
 
 
Tests of Between-Subjects Effects 
Dependent Variable: Ratio pAKT (T308) 
Source 
Type III Sum 
of Squares df Mean Square F Sig. 
Partial Eta 
Squared 
Corrected 
Model 
.055a 3 .018 3.548 .038 .400 
Intercept 1.282 1 1.282 249.749 .000 .940 
Pregnancy .010 1 .010 1.964 .180 .109 
Diet .035 1 .035 6.761 .019 .297 
Pregnancy * 
Diet 
.003 1 .003 .601 .449 .036 
Error .082 16 .005    
Total 1.530 20     
Corrected Total .137 19     
a. R Squared = .400 (Adjusted R Squared = .287) 
 
 
 
 
 
  
 
157 
 
Curriculum Vitae 
 
Name:   Jacky Chiu 
 
Post-secondary  University of Western Ontario 
Education and  London, Ontario, Canada 
Degrees:   2007-2011 BMSc 
 
The University of Western Ontario 
London, Ontario, Canada 
2013-2015 MSc 
 
 
Honours and Awards:   
 
Canadian Institute of Health and Research Travel Award  2014 
Children’s Health Research Institute Travel Award 2013 
Ontario Graduate Scholarship (Queen Elizabeth II Graduate Scholarship in Science and 
Technology)  2013-2014 
Obstetrics and Gynecology (London Ontario, Canada) Graduate Scholarship 2012-2014 
Western Graduate Research Scholarship  2012-2014 
 
 
Related Work Experience: 
  
Teaching Assistant.  2012 – 2014 
- Fetal Physiology 4700B. Western University 
 
Thesis in Physiology and Pharmacology 2012 – 2014 
- Studying effects of ginseng’s immune-modulating effects on placenta 
 
Research Student, Department of Physiology and Pharmacology.  2009 – 2010 
- Investigated Peroxisome Proliferator-Activated Receptor and Resveratrol on changes in 
activators of muscle oxidative metabolism 
- Explored the alterations in lung development following diaphragmatic hernia in sheep 
   
 
 
 
 
 
 
158 
 
Publications: 
 
Regnault, T. R., Zhao, L., Chiu, J. S., Gottheil, S. K., Foran, A., & Yee, S. P. (2010). 
Peroxisome Proliferator-Activated Receptor-β/δ,-γ Agonists and Resveratrol Modulate 
Hypoxia Induced Changes in Nuclear Receptor Activators of Muscle Oxidative 
Metabolism. PPAR research, 2010. 
 
Emmerton-Coughlin H.M.A, Martin K.K., Chiu J.S., Zhao L., Scott L.A., Regnault 
T.R.H., and Bütter A. WNT Signaling Pathway in an Ovine Model of Congenital 
Diaphragmatic Hernia is down regulated. Submitted to Frontiers in Surgery, Pediatric 
Surgery. August 2014. 
 
 
Extracurricular Activities: 
 
Volunteer Friendly Visitor, Children’s Aid Society of London  2008 – 2014 
Phys/Pharm Intramural Soccer  2012 – 2014 
Captain, Phys/Pharm Intramural Indoor Volleyball  2013 
Richmond Hill Soccer League  2013 
Volunteer, YMCA of Western Ontario  2009 – 2012 
Volunteer, Western University March Break Open House  2010 
Volunteer, Boys’ and Girls’ Club of London  2009 – 2010 
Volunteer, TD Summer Reading Club 2010 
Volunteer, United Christian’s Hospital of Hong Kong  2008 
Executive, Hong Kong Connexion Club of University of Western Ontario  2008-2009 
Volunteer, UNICEF of Western Ontario 2008-2009 
Chartered Member, St John Ambulance of York East 2003-2008 
 
